{"gene":"MCL1","run_date":"2026-06-10T02:59:50","timeline":{"discoveries":[{"year":2003,"finding":"In uninfected cells, BAK is complexed with MCL-1. Upon adenovirus E1A expression, MCL-1 is specifically down-regulated through protein destabilization and mRNA loss, releasing BAK from the MCL-1-BAK complex. Loss of MCL-1 was required to initiate apoptosis, as restoration of MCL-1 expression rescued infected cells from E1A-induced apoptosis. MCL-1 thus maintains BAK in an inactive state.","method":"Co-immunoprecipitation, Western blotting, rescue expression experiments in adenovirus-infected cells","journal":"Genes & development","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal Co-IP establishing BAK complex, combined with rescue experiments demonstrating functional requirement; multiple orthogonal methods in one study","pmids":["14633975"],"is_preprint":false},{"year":2002,"finding":"Tankyrase 1 physically interacts with both MCL-1L and MCL-1S isoforms via its first 10 ankyrin repeats binding to a 25-amino-acid stretch in the N-terminus of MCL-1. Overexpression of tankyrase 1 antagonizes MCL-1L-mediated cell survival and MCL-1S-induced cell death, and decreases MCL-1 protein levels. No ADP-ribosylation of MCL-1 was detected; instead, MCL-1 overexpression suppresses ADP-ribosylation of the tankyrase substrate TRF1.","method":"Yeast two-hybrid screening, co-immunoprecipitation in mammalian cells, truncation mutant analysis, overexpression functional assays","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — yeast two-hybrid plus Co-IP plus functional assays, single lab, multiple orthogonal methods","pmids":["12475993"],"is_preprint":false},{"year":2010,"finding":"MCL-1 degradation can occur independently of ubiquitination. An MCL-1 mutant lacking all lysine residues (MCL-1(KR)) that cannot be ubiquitinated is degraded at a rate similar to wild-type MCL-1 under both basal and stressed conditions. Unmodified, in vitro-translated MCL-1 is degraded by the 20S proteasome in a cell-free system.","method":"Ubiquitination-deficient MCL-1(KR) mutant expression, blocking E1 ubiquitin-activating enzyme, in vitro 20S proteasome degradation assay, primary lymphocyte experiments","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro proteasome reconstitution assay combined with mutagenesis (KR mutant) and E1 inhibition, multiple orthogonal methods in single study","pmids":["20385764"],"is_preprint":false},{"year":2010,"finding":"MCL-1 localizes to sites of DNA double-strand breaks (co-localizes with γ-H2AX and NBS1 by immunoprecipitation and immunofluorescence, and is directly recruited adjacent to DSB sites). MCL-1-deficient MEFs show delayed Chk1 phosphorylation and delayed γ-H2AX appearance after etoposide treatment. Loss of MCL-1 results in greater accumulation of chromosomal abnormalities after repeated etoposide treatment, indicating a role in DNA damage checkpoint response and genome integrity.","method":"Co-immunoprecipitation with γ-H2AX and NBS1, immunofluorescence co-staining, site-specific DSB recruitment assay, comparison of Mcl-1−/− vs. wild-type MEFs, chromosomal aberration analysis","journal":"Cell cycle (Georgetown, Tex.)","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct DSB recruitment assay plus Co-IP plus KO MEF functional analysis; single lab, multiple orthogonal methods","pmids":["20647761"],"is_preprint":false},{"year":2013,"finding":"Cardiac-specific ablation of Mcl-1 results in fatal dilated cardiomyopathy with loss of cardiac contractility, abnormal mitochondrial ultrastructure, and defective mitochondrial respiration. Genetic co-deletion of Bax and Bak largely rescues lethality and cardiac function, but mitochondrial ultrastructural abnormalities and deficient respiration persist, indicating that MCL-1 has a function in mitochondrial physiology beyond apoptosis suppression.","method":"Conditional cardiac-specific Mcl-1 knockout mice, genetic epistasis with Bax/Bak double knockout, electron microscopy of mitochondrial ultrastructure, mitochondrial respiration assays","journal":"Genes & development","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — conditional KO with genetic epistasis (Bax/Bak rescue), electron microscopy, and respiration assays; multiple orthogonal methods demonstrating separable apoptotic vs. mitochondrial functions","pmids":["23788622"],"is_preprint":false},{"year":2012,"finding":"MCL-1's antiapoptotic activity is restricted to the outer mitochondrial membrane (OMM), whereas its function in maintaining normal mitochondrial morphology and energy production requires localization to the matrix. These two functions depend on separate mitochondrial sublocalizations.","method":"Subcellular fractionation, functional studies with localization variants (review synthesizing multiple experimental studies)","journal":"Trends in cell biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — review synthesizing direct localization and functional experiments across multiple studies; localization tied to distinct functional consequences","pmids":["23026029"],"is_preprint":false},{"year":2014,"finding":"SCF-Fbw7 E3 ubiquitin ligase mediates MCL-1 ubiquitination and proteasomal degradation in a GSK3 phosphorylation-dependent manner. Loss of Fbw7 tumor suppressor results in MCL-1 overexpression and resistance to ABT-737. Reconstitution of Fbw7 or depletion of MCL-1 in Fbw7-deficient cells restores ABT-737 sensitivity.","method":"Ubiquitination assays, GSK3 inhibition experiments, Fbw7 reconstitution, Mcl-1 siRNA knockdown, cell viability assays in T-ALL cell lines","journal":"Oncotarget","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ubiquitination assays plus rescue experiments; single lab, multiple approaches","pmids":["21608150"],"is_preprint":false},{"year":2017,"finding":"Hsp90 inhibition promotes GSK3β-dependent phosphorylation of MCL-1, which then binds to FBW7 and undergoes ubiquitination and proteasomal degradation. Blocking MCL-1 phosphorylation by genetic knock-in abrogates its degradation and confers resistance to Hsp90 inhibitors in vitro and in vivo.","method":"GSK3β inhibitor experiments, Mcl-1 phospho-mutant knock-in, ubiquitination assays, FBW7 mutation analysis in colorectal cancer cells, in vivo xenograft models","journal":"Molecular cancer therapeutics","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — genetic knock-in of phospho-mutant plus ubiquitination assays plus in vivo validation; multiple orthogonal methods establishing mechanism","pmids":["28619760"],"is_preprint":false},{"year":2009,"finding":"MCL-1 is rapidly degraded in hepatocytes in response to palmitate via a PKCθ-dependent, proteasome-dependent pathway. PKCθ promotes phosphorylation of MCL-1 at Ser159. An MCL-1 S159A mutant is resistant to palmitate-induced degradation and improves cell survival. Overexpression of a ubiquitin-resistant MCL-1 mutant attenuates palmitate-induced lipoapoptosis.","method":"Proteasome inhibitor experiments, novel PKC inhibitor (rottlerin), shRNA knockdown of PKCθ, PKCθ genetic deletion in primary hepatocytes, phospho-immunoblot of MCL-1 Ser159, MCL-1 S159A mutant expression, ubiquitin-resistant Mcl-1 mutant overexpression","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — site-directed mutagenesis (S159A) plus genetic KO plus pharmacological inhibition, multiple orthogonal approaches in single study","pmids":["19734538"],"is_preprint":false},{"year":2007,"finding":"Cell detachment from ECM rapidly degrades MCL-1 via a GSK-3β-dependent proteasomal pathway and transcriptionally up-regulates Bim. MCL-1 degradation in the presence of Bim is sufficient to induce anoikis. Dysregulation of this MCL-1 degradation/Bim induction axis contributes to anoikis resistance in metastatic cancer cells.","method":"GSK-3β inhibition, proteasome inhibitor experiments, knockdown of MCL-1 and Bim, comparison of non-metastatic vs. metastatic cell lines, in vivo metastasis assay","journal":"Cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pharmacological pathway manipulation plus siRNA knockdown plus in vivo validation; single lab, multiple complementary approaches","pmids":["18006817"],"is_preprint":false},{"year":2017,"finding":"MCL-1 acts as a functional switch between homologous recombination (HR) and non-homologous end-joining (NHEJ) DNA repair pathways. MCL-1 depletion reduces HR and enhances NHEJ, while MCL-1 overexpression increases HR over NHEJ. MCL-1 directly interacts with the Ku protein complex via its BH1 and BH3 domains to inhibit Ku-mediated NHEJ. MCL-1 also promotes DNA resection by the Mre11 complex. MCL-1 expression peaks in S/G2 phase in a cell-cycle-regulated manner during HR.","method":"CRISPR/Cas9 and shRNA depletion, HR/NHEJ reporter assays, co-immunoprecipitation of MCL-1 with Ku complex, domain deletion mutants (BH1, BH3), cell cycle analysis, in vivo lung cancer xenograft experiments with small molecule MI-223","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — direct interaction via Co-IP with domain mapping, functional HR/NHEJ assays, KO/KD, and in vivo validation; multiple orthogonal methods in single rigorous study","pmids":["29227281"],"is_preprint":false},{"year":2019,"finding":"MCL-1 directly interacts with Akt via its PEST domain binding to the pleckstrin homology (PH) domain of Akt. This Mcl-1/PH domain interaction disrupts intramolecular PH/kinase domain interactions of Akt, thereby activating Akt. Depletion of MCL-1 by CRISPR/Cas9 or shRNA significantly decreases Akt activity and suppresses lung cancer cell growth in vitro and in xenografts.","method":"CRISPR/Cas9 and shRNA depletion of MCL-1, co-immunoprecipitation of MCL-1 with Akt, domain-specific interaction mapping (PEST domain vs. PH domain), Akt activity measurements, xenograft models, small molecule PH-687 disruption of MCL-1/Akt interaction","journal":"Cancer research","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — direct interaction via Co-IP with domain mapping, CRISPR KO, functional Akt activity assay, and in vivo xenograft validation; multiple orthogonal methods","pmids":["31662324"],"is_preprint":false},{"year":2016,"finding":"A cysteine residue (C286) at a site distant from the BH3-binding groove of MCL-1 serves as an allosteric regulatory site. Covalent small-molecule modification of C286 impairs the BH3 binding capacity of MCL-1 and its suppression of BAX, as recapitulated by C286W mutagenic mimicry in vitro and in mouse cells.","method":"Covalent small-molecule modification, C286W mutagenesis, structure-function analysis, in vitro BH3 binding assay, BAX suppression assay in mouse cells, hydrogen-deuterium exchange mass spectrometry","journal":"Nature structural & molecular biology","confidence":"High","confidence_rationale":"Tier 1 / Strong — structure-function analysis with site-directed mutagenesis, in vitro functional assay, and cell-based validation; multiple orthogonal approaches in single rigorous study","pmids":["27159560"],"is_preprint":false},{"year":2012,"finding":"SRSF1 and SRSF5 RNA-binding proteins regulate alternative splicing of MCL-1 pre-mRNA. Knockdown of SRSF1 shifts splicing toward pro-apoptotic MCL-1S in breast cancer cells. SRSF1 also affects MCL-1 protein stability and translation in a cell-context-dependent manner.","method":"siRNA knockdown of SRSF1 and SRSF5, RT-PCR splicing analysis, Western blotting in breast cancer and choriocarcinoma cell lines","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — RNAi knockdown of splicing factors with direct splicing readout; single lab, two orthogonal methods (splicing and protein level)","pmids":["23284704"],"is_preprint":false},{"year":2018,"finding":"hnRNP F, H1, and K RNA-binding proteins regulate alternative splicing of MCL-1 pre-mRNA. siRNA knockdown of hnRNP K and the hnRNP F/H family switches splicing toward pro-apoptotic MCL-1S. Specific binding sites for these factors were identified by RNA immunoprecipitation using a MCL-1 minigene construct. Triple knockdown achieves up to 30-fold increase in MCL-1S levels and activates the mitochondrial cell death pathway.","method":"siRNA knockdown, RT-PCR splicing analysis, RNA immunoprecipitation, MCL-1 minigene construct, apoptosis assays","journal":"RNA biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — RNA immunoprecipitation plus minigene construct plus functional apoptosis readout; single lab, multiple orthogonal methods","pmids":["30468106"],"is_preprint":false},{"year":2015,"finding":"MCL-1 involvement in mitochondrial dynamics is mediated through its two isoforms: increased MCL-1S/L ratio (promoted by splice-switching antisense oligonucleotides) induces mitochondrial hyperfusion in a Drp1-dependent manner and increases mitochondrial calcium accumulation. The balance between MCL-1L and MCL-1S isoforms regulates mitochondrial fusion/fission machinery.","method":"Splice-switching antisense oligonucleotides, measurement of mitochondrial morphology, mitochondrial calcium accumulation assays, Drp1-dependence analysis","journal":"Molecular biology of the cell","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct manipulation of isoform ratio via ASOs with functional mitochondrial readout; single lab, multiple measurements","pmids":["26538029"],"is_preprint":false},{"year":2021,"finding":"The deubiquitinase USP13 binds to, deubiquitinates, and stabilizes MCL-1 in cervical cancer cells. Depletion of USP13 reduces MCL-1 protein levels and inhibits cell proliferation. USP13 and MCL-1 protein levels correlate in cervical cancer tissue.","method":"Co-immunoprecipitation of USP13 with MCL-1, ubiquitination assays, siRNA knockdown, proliferation assays, IHC correlation in tissue","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP plus ubiquitination assay plus functional KD; single lab, multiple orthogonal methods","pmids":["33627786"],"is_preprint":false},{"year":2022,"finding":"Skp2 stabilizes MCL-1 by competing with the E3 ligase FBW7-mediated MCL-1 ubiquitination. Depletion of Skp2 enhances FBW7-mediated MCL-1 ubiquitination and degradation, increasing irradiation-induced apoptosis. The Skp2/MCL-1 axis controls radioresistance in colorectal cancer.","method":"Co-immunoprecipitation, ubiquitination analysis, CRISPR-Cas9 Skp2 knockout, Western blotting, xenograft experiments, flow cytometry","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP plus ubiquitination assay plus CRISPR KO plus in vivo validation; single lab, multiple complementary approaches","pmids":["35301297"],"is_preprint":false},{"year":2022,"finding":"Stabilization of MCL-1 by E3 ligase TRAF4 occurs through a TRAF4-Akt-GSK3β signaling axis. TRAF4 promotes Akt K63-mediated ubiquitination and activation; TRAF4 knockout inhibits Akt phosphorylation and upregulates GSK3β activity, leading to increased MCL-1 S159 phosphorylation that disrupts MCL-1 interaction with deubiquitinase JOSD1, thereby promoting MCL-1 ubiquitination and degradation.","method":"Co-immunoprecipitation of TRAF4 with Akt and MCL-1, ubiquitination analysis, GSK3β activity assays, phospho-specific Western blotting (MCL-1 S159), TRAF4 knockout, xenograft experiments","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP plus phosphorylation mapping plus KO experiments; single lab, multiple orthogonal methods","pmids":["36535926"],"is_preprint":false},{"year":2021,"finding":"PP2A phosphatase stabilizes MCL-1 in multiple myeloma cells by dephosphorylating MCL-1 at Ser159 and/or Thr163. PP2A inhibition by okadaic acid increases MCL-1 phosphorylation at these sites and destabilizes MCL-1. The MCL-1 half-life in MM is regulated by counteracting functions of JNK kinase and PP2A phosphatase.","method":"Phosphatase siRNA screen, PP2A inhibitor (okadaic acid), phospho-specific Western blotting, combined kinase/phosphatase inhibitor experiments, MCL-1 half-life measurements","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — siRNA screen plus pharmacological validation plus phospho-site specific analysis; single lab, multiple orthogonal methods","pmids":["33658484"],"is_preprint":false},{"year":2017,"finding":"FBXO4 functions as an E3 ubiquitin ligase for MCL-1, interacting with MCL-1 and promoting its ubiquitination and proteasomal degradation. Knockdown of FBXO4 elevates MCL-1 protein levels and increases cell survival and chemotherapy resistance, while ectopic FBXO4 expression has opposite effects.","method":"Co-immunoprecipitation, ubiquitination assays, FBXO4 knockdown and overexpression, Western blotting for MCL-1 protein levels, cell viability assays","journal":"Cancer gene therapy","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP plus ubiquitination assay plus reciprocal KD/OE functional experiments; single lab, multiple orthogonal methods","pmids":["28776569"],"is_preprint":false},{"year":2012,"finding":"Caveolin-1 (Cav-1) regulates MCL-1 stability through direct protein-protein interaction, preventing MCL-1 ubiquitination and degradation during anoikis. Cav-1-overexpressing cells show elevated MCL-1 and MCL-1-Cav-1 complex, while Cav-1 knockdown reduces MCL-1 and increases its ubiquitination.","method":"Co-immunoprecipitation, immunocytochemistry, Cav-1 overexpression and knockdown, ubiquitination assays, anoikis assays","journal":"American journal of physiology. Cell physiology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP plus ubiquitination assay plus reciprocal gain/loss-of-function; single lab, multiple orthogonal methods","pmids":["22277751"],"is_preprint":false},{"year":2022,"finding":"MCL-1 is a master regulator of fatty acid oxidation (FAO) in MCL-1-dependent hematologic cancer cells. FAO regulation by MCL-1 is independent of its anti-apoptotic activity, as demonstrated by metabolomic, proteomic, and genomic profiling of MCL-1-dependent leukemia cells lacking an intact apoptotic pathway. Genetic deletion of Mcl-1 results in transcriptional downregulation of FAO pathway proteins, making cells susceptible to glucose withdrawal-triggered cell death even when apoptosis is blocked.","method":"Mcl-1 genetic deletion, metabolomic profiling, proteomic profiling, genomic profiling, glucose withdrawal experiments in apoptosis-deficient cells","journal":"Cell reports","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — genetic deletion with metabolomic/proteomic/genomic profiling plus functional apoptosis-independent validation using multiple orthogonal approaches","pmids":["36198266"],"is_preprint":false},{"year":2022,"finding":"MCL-1 suppresses non-selective starvation-induced autophagy but promotes selective autophagy (mitophagy) of dysfunctional mitochondria. MCL-1 interacts with the mitophagy receptor Bnip3, and this interaction increases during mitochondrial stress. MCL-1-mediated mitochondrial clearance is partially dependent on its LC3-interacting regions (LIR motifs), as mutation of LIR sites significantly reduces MCL-1-mediated mitochondrial clearance.","method":"Cardiac-specific MCL-1 overexpression, autophagic flux assays, mitophagy assays, co-immunoprecipitation of MCL-1 with Bnip3, LIR motif mutagenesis, mitochondrial depolarization experiments","journal":"Cells","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP plus LIR mutagenesis plus functional autophagy/mitophagy assays; single lab, multiple orthogonal methods","pmids":["35563775"],"is_preprint":false},{"year":2020,"finding":"The transmembrane domain (TMD) of MCL-1 forms homooligomers in the mitochondrial membrane and competes with full-length MCL-1 for its antiapoptotic function. MCL-1 TMD can also heterooligomerize with the Bok TMD predominantly at the mitochondrial membrane. Coexpression of MCL-1 and Bok TMDs increases ER-mitochondria associated membranes. Cancer-associated somatic mutations in the MCL-1 TMD alter the TMD interaction pattern to enhance MCL-1 antiapoptotic activity.","method":"Oligomerization assays, subcellular fractionation, apoptosis assays, mutagenesis of cancer-associated TMD variants, ER-mitochondria contact site analysis","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct TMD oligomerization assays plus mutagenesis plus functional apoptosis readout; single lab, multiple orthogonal methods","pmids":["33093207"],"is_preprint":false},{"year":2014,"finding":"STAT3 and MCL-1 are direct interacting partners during embryo implantation, with the interaction regulated by estrogen and progesterone. Association of MCL-1 with STAT3 modulates MCL-1's normal anti-apoptotic activity, resulting in pro-apoptotic effects and decreased cellular invasion in MCF7 cells.","method":"MALDI-TOF analysis, far-western analysis, co-localization studies, co-transfection experiments, apoptosis and invasion assays","journal":"Journal of cell science","confidence":"Low","confidence_rationale":"Tier 3 / Weak — co-localization and co-transfection without reciprocal Co-IP; single lab, limited mechanistic follow-up for STAT3 as direct binding partner","pmids":["24481815"],"is_preprint":false},{"year":2003,"finding":"During apoptosis, MCL-1 protein levels decline through both caspase-dependent (affecting mRNA) and proteasome-dependent (affecting protein) pathways. Staurosporine reduces MCL-1 mRNA through caspase-dependent transcriptional inhibition of the MCL-1 promoter, while aspirin reduces MCL-1 protein via cap-dependent translation inhibition with eIF2α phosphorylation, without affecting mRNA.","method":"Caspase inhibitor (Z-VAD.fmk), proteasome inhibitor (MG132), actinomycin D, luciferase reporter constructs for MCL-1 promoter, IRES-luciferase translation reporter, eIF2α phosphorylation assays, cycloheximide treatment","journal":"Archives of biochemistry and biophysics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reporter assays plus pharmacological pathway dissection plus multiple orthogonal approaches; single lab","pmids":["12941295"],"is_preprint":false},{"year":2013,"finding":"Notch1 directly controls the MCL-1 promoter through a conserved CSL/RBP-Jκ binding site. Notch1 upregulation in macrophages treated with PPD or infected with BCG correlates with MCL-1 upregulation. Silencing Notch1 decreases MCL-1 protein expression, and gamma-secretase inhibition (blocking Notch processing) reduces both Notch1 and MCL-1 levels with increased apoptosis.","method":"Chromatin immunoprecipitation (ChIP) of Notch1 at MCL-1 promoter, gamma-secretase inhibitor experiments, Notch1 siRNA knockdown, promoter sequence analysis, Western blotting and RT-PCR","journal":"Cellular & molecular immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP establishing direct promoter binding plus pharmacological and siRNA validation; single lab, multiple orthogonal methods","pmids":["23872918"],"is_preprint":false},{"year":2018,"finding":"Phosphorylation of Bim regulates MCL-1 stability and binding specificity. Constitutively phosphorylated Bim stabilizes MCL-1 in RPCI-WM1 cells. Phospho-mimetic and unphosphorylatable Bim mutations result in altered MCL-1 stability and distinct Bim binding patterns to antiapoptotic proteins, linking Bim phosphorylation to enforcement of MCL-1 dependence.","method":"Phospho-mimetic and phospho-deficient Bim mutant expression, MCL-1 stability assays, co-immunoprecipitation to assess Bim-MCL-1 binding, cell viability assays","journal":"The FEBS journal","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — phospho-mutant analysis plus Co-IP plus functional stability assay; single lab, multiple approaches","pmids":["29775995"],"is_preprint":false},{"year":2016,"finding":"During mitotic arrest (taxol treatment), proteasome-mediated MCL-1 degradation occurs independently of APC/C-Cdc20, FBW7, or MULE E3 ubiquitin ligases. MCL-1 is continuously synthesized during mitosis. Blocking proteasome-mediated degradation inhibits taxol-induced mitotic apoptosis in an MCL-1-dependent manner. Overexpression of MCL-1 extends the time from mitotic entry to exit under taxol, while MCL-1 inhibition accelerates mitotic exit, suggesting MCL-1 competes with Cyclin B1 for the proteolysis machinery.","method":"Proteasome inhibitor experiments, siRNA knockdown of APC/C-Cdc20/FBW7/MULE, time-lapse microscopy, MCL-1 overexpression and inhibition, Cyclin B1 degradation assays","journal":"Oncotarget","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple E3 ligase knockdowns plus MCL-1 gain/loss-of-function plus time-lapse functional analysis; single lab, multiple orthogonal approaches","pmids":["26769847"],"is_preprint":false},{"year":2011,"finding":"A novel 'reverse BH3' (rBH3) binding motif was identified for MCL-1 through phage display screening. rBH3 peptides bind selectively to the BH3-binding groove of MCL-1 over Bcl-xL, with a reverse organization of conserved hydrophobic and acidic residues compared to canonical BH3 sequences.","method":"Phage display library screening with Sabutoclax as competitor, NMR spectroscopy, fluorescence polarization displacement assays, alanine scanning","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — NMR plus fluorescence polarization plus alanine scanning; single lab, multiple biophysical methods","pmids":["21953453"],"is_preprint":false},{"year":2023,"finding":"MCL-1 inhibitors (AMG-176 and AZD5991) induce MCL-1 protein stability predominantly through defective MCL-1 ubiquitination via enhanced deubiquitination (through USP9x) and dissociation of MCL-1 from Noxa (leading to Noxa degradation) and from Bak/Bax. Mule E3 ligase is destabilized. ERK-mediated MCL-1 Thr163 phosphorylation partially contributes. WP1130 (global DUB inhibitor) abrogates MCL-1 induction.","method":"Protein half-life assays, reverse-phase protein array, Co-IP, phosphorylation analysis, ubiquitination and de-ubiquitination assays in vitro, DUB inhibitor experiments, molecular simulation and modeling","journal":"Clinical cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP plus in vitro ubiquitination assays plus pharmacological DUB inhibition; single lab, multiple orthogonal methods","pmids":["36346691"],"is_preprint":false}],"current_model":"MCL-1 is a multifunctional anti-apoptotic BCL-2 family protein that primarily sequesters pro-apoptotic proteins (BAK, BAX, BIM) at the outer mitochondrial membrane to prevent cytochrome c release; its stability is governed by a complex post-translational network involving phosphorylation (at Ser159/Thr163 by GSK3β, PKCθ, CDK5; dephosphorylated by PP2A) targeting it for ubiquitination by multiple E3 ligases (FBW7, MULE, FBXO4, FBXO4, TRAF4-Akt axis) and stabilization by deubiquitinases (USP9X, USP13), with additional ubiquitin-independent proteasomal degradation via the 20S proteasome; beyond apoptosis regulation, MCL-1 localizes to the mitochondrial matrix to support mitochondrial respiration and morphology, is recruited to DNA double-strand break sites where it promotes ATR-Chk1 checkpoint signaling, acts as a functional switch between HR and NHEJ DNA repair via direct interaction with Ku through its BH1/BH3 domains, interacts with and activates Akt through its PEST domain, regulates fatty acid oxidation transcriptionally independent of its apoptotic function, and modulates mitophagy through LC3-interacting regions and interaction with Bnip3."},"narrative":{"mechanistic_narrative":"MCL-1 is an anti-apoptotic BCL-2 family protein that maintains pro-apoptotic effectors in an inactive state at the mitochondrion to prevent commitment to programmed cell death [PMID:14633975]. Its core survival function rests on its BH3-binding groove, which holds BAK in an inactive complex; loss of MCL-1 releases BAK and licenses apoptosis [PMID:14633975], and an allosteric cysteine (C286) distant from this groove tunes BH3 binding and BAX suppression [PMID:27159560]. The anti-apoptotic activity is restricted to the outer mitochondrial membrane, whereas a separable matrix-localized pool supports mitochondrial respiration and morphology — cardiac ablation of Mcl-1 causes fatal cardiomyopathy with respiratory defects that persist even when apoptosis is blocked by Bax/Bak co-deletion [PMID:23788622, PMID:23026029]. Beyond apoptosis, MCL-1 acts as a transcriptional master regulator of fatty acid oxidation independently of its apoptotic role [PMID:36198266], is recruited to DNA double-strand breaks to support ATR-Chk1 checkpoint signaling and genome integrity [PMID:20647761], and functions as a switch between homologous recombination and non-homologous end-joining by directly binding the Ku complex through its BH1/BH3 domains [PMID:29227281]. MCL-1 also directly binds and activates Akt via its PEST domain [PMID:31662324] and modulates mitophagy through LC3-interacting regions and interaction with the receptor Bnip3 [PMID:35563775]. The protein is short-lived and its abundance is set by a dense post-translational network: GSK3β-, PKCθ- and ERK-dependent phosphorylation (notably at Ser159/Thr163) primes it for ubiquitination by E3 ligases including SCF-Fbw7 and FBXO4, opposed by PP2A-mediated dephosphorylation, stabilizing deubiquitinases (USP13, USP9x), and competing factors such as Skp2 and TRAF4 [PMID:21608150, PMID:28619760, PMID:19734538, PMID:33627786, PMID:35301297, PMID:36535926, PMID:33658484, PMID:28776569, PMID:36346691]. MCL-1 can additionally be degraded ubiquitin-independently by the 20S proteasome [PMID:20385764], and its pro-survival versus pro-death balance is set upstream by alternative splicing that produces MCL-1L and MCL-1S isoforms [PMID:23284704, PMID:30468106, PMID:26538029].","teleology":[{"year":2003,"claim":"Established the core anti-apoptotic mechanism: that MCL-1 directly restrains a pro-apoptotic effector rather than acting only as a general survival signal.","evidence":"Co-IP of MCL-1 with BAK plus rescue experiments in adenovirus-infected cells where E1A-driven MCL-1 loss releases BAK and triggers apoptosis","pmids":["14633975"],"confidence":"High","gaps":["Did not resolve the structural basis of the BAK interaction","Did not address other effectors (BAX, BIM) in the same system"]},{"year":2003,"claim":"Showed MCL-1 abundance is controlled at multiple layers during apoptosis, distinguishing transcriptional, translational and proteasomal routes of loss.","evidence":"Promoter and IRES reporter assays, caspase and proteasome inhibitors, and eIF2α phosphorylation analysis","pmids":["12941295"],"confidence":"Medium","gaps":["Did not identify the responsible E3 ligase","Mechanism linking caspase activity to mRNA loss not defined"]},{"year":2009,"claim":"Mapped a specific kinase-to-degradation axis by identifying Ser159 phosphorylation as a degradation trigger under lipotoxic stress.","evidence":"PKCθ genetic deletion, rottlerin inhibition, phospho-Ser159 immunoblot, and S159A mutant in primary hepatocytes","pmids":["19734538"],"confidence":"High","gaps":["Did not identify the E3 ligase acting downstream of Ser159 phosphorylation","Generalizability beyond hepatocyte lipoapoptosis untested"]},{"year":2010,"claim":"Demonstrated MCL-1 degradation can be entirely ubiquitin-independent, revealing a 20S-proteasome route alongside the canonical ubiquitin pathway.","evidence":"Lysine-less MCL-1(KR) mutant, E1 inhibition, and cell-free 20S proteasome degradation of in vitro-translated MCL-1","pmids":["20385764"],"confidence":"High","gaps":["Relative contribution of ubiquitin-dependent vs independent routes in vivo unclear","What targets MCL-1 to the 20S proteasome unresolved"]},{"year":2010,"claim":"Extended MCL-1 function into the DNA damage response, showing a nuclear/DSB role in checkpoint signaling distinct from mitochondrial apoptosis.","evidence":"Co-IP with γ-H2AX and NBS1, site-specific DSB recruitment, and delayed Chk1 phosphorylation in Mcl-1−/− MEFs","pmids":["20647761"],"confidence":"Medium","gaps":["Direct molecular partner at the break site not defined here","How nuclear recruitment is regulated unknown"]},{"year":2012,"claim":"Resolved that MCL-1's apoptotic and metabolic functions are spatially separated within the mitochondrion.","evidence":"Subcellular fractionation and localization-variant functional studies (review synthesizing direct experiments)","pmids":["23026029"],"confidence":"Medium","gaps":["Import mechanism into the matrix not defined","Molecular partners of the matrix pool unidentified"]},{"year":2013,"claim":"Provided in vivo proof that MCL-1 has an essential apoptosis-independent role in mitochondrial physiology.","evidence":"Cardiac-specific Mcl-1 KO with Bax/Bak epistasis, electron microscopy, and respiration assays","pmids":["23788622"],"confidence":"High","gaps":["Molecular mechanism connecting MCL-1 to respiration not identified","Matrix interacting partners unknown"]},{"year":2007,"claim":"Linked MCL-1 turnover to anoikis and metastasis through a GSK-3β/proteasome/Bim axis.","evidence":"GSK-3β and proteasome inhibition, MCL-1/Bim knockdown, and metastatic vs non-metastatic cell comparison with in vivo metastasis assay","pmids":["18006817"],"confidence":"Medium","gaps":["E3 ligase downstream of GSK-3β not identified here","Direct link to phospho-sites not mapped"]},{"year":2012,"claim":"Identified caveolin-1 as a stabilizing binding partner that protects MCL-1 from ubiquitination during anoikis.","evidence":"Co-IP, reciprocal Cav-1 overexpression/knockdown, and ubiquitination assays","pmids":["22277751"],"confidence":"Medium","gaps":["Binding interface not mapped","Whether Cav-1 blocks a specific E3 unknown"]},{"year":2012,"claim":"Identified tankyrase 1 as an N-terminal binding partner regulating MCL-1 levels independent of ADP-ribosylation.","evidence":"Yeast two-hybrid, Co-IP, truncation mapping, and overexpression functional assays","pmids":["12475993"],"confidence":"Medium","gaps":["Mechanism of level reduction not defined","Physiological relevance untested"]},{"year":2012,"claim":"Established splicing factor control of the MCL-1L/MCL-1S balance, defining an upstream determinant of pro- vs anti-apoptotic output.","evidence":"SRSF1/SRSF5 siRNA knockdown with RT-PCR splicing readout in breast cancer cells","pmids":["23284704"],"confidence":"Medium","gaps":["Direct binding sites not mapped in this study","Context-dependence mechanism unclear"]},{"year":2018,"claim":"Expanded the splicing regulatory network and mapped binding sites controlling the pro-apoptotic MCL-1S switch.","evidence":"hnRNP F/H1/K knockdown, RNA-IP, MCL-1 minigene, and apoptosis assays","pmids":["30468106"],"confidence":"Medium","gaps":["Interplay with SR proteins not resolved","In vivo relevance untested"]},{"year":2013,"claim":"Defined transcriptional control of MCL-1 by Notch1 through a direct promoter element in an immune context.","evidence":"ChIP at the MCL-1 promoter, gamma-secretase inhibition, and Notch1 siRNA in macrophages","pmids":["23872918"],"confidence":"Medium","gaps":["Cofactors at the CSL site not defined","Generalizability beyond macrophages unknown"]},{"year":2014,"claim":"Linked Fbw7 loss to MCL-1 overexpression and BH3-mimetic resistance, establishing a clinically relevant degradation pathway.","evidence":"Ubiquitination assays, GSK3 inhibition, Fbw7 reconstitution and Mcl-1 knockdown in T-ALL lines","pmids":["21608150"],"confidence":"Medium","gaps":["Phospho-degron not directly mapped here","Dependence on specific phospho-sites not defined"]},{"year":2014,"claim":"Proposed STAT3 as a context-dependent partner that inverts MCL-1 function toward pro-apoptotic outcomes during implantation.","evidence":"MALDI-TOF, far-western, co-localization and co-transfection with apoptosis/invasion assays","pmids":["24481815"],"confidence":"Low","gaps":["No reciprocal Co-IP to confirm direct binding","Mechanism of functional inversion not defined","Single-lab limited follow-up"]},{"year":2016,"claim":"Identified an allosteric regulatory cysteine (C286) outside the BH3 groove that controls MCL-1's effector-suppressing capacity.","evidence":"Covalent C286 modification, C286W mutagenesis, in vitro BH3 binding and BAX suppression assays, and HDX-MS","pmids":["27159560"],"confidence":"High","gaps":["Endogenous physiological ligand of C286 unknown","Whether oxidation modifies C286 in cells untested"]},{"year":2016,"claim":"Defined a mitosis-specific, ligase-independent route of MCL-1 degradation that gates taxol-induced mitotic apoptosis.","evidence":"siRNA of APC/C-Cdc20, FBW7, MULE, proteasome inhibition, time-lapse microscopy and MCL-1 gain/loss-of-function","pmids":["26769847"],"confidence":"Medium","gaps":["The degradation machinery used during mitosis not identified","Mechanism of competition with Cyclin B1 unclear"]},{"year":2011,"claim":"Characterized a distinct 'reverse BH3' binding mode selective for the MCL-1 groove, informing inhibitor design.","evidence":"Phage display, NMR, fluorescence polarization displacement and alanine scanning","pmids":["21953453"],"confidence":"Medium","gaps":["No endogenous rBH3 protein partner identified","Cellular relevance untested"]},{"year":2017,"claim":"Coupled Hsp90 inhibition to MCL-1 degradation via GSK3β-dependent phosphorylation and FBW7 recruitment, validated in vivo.","evidence":"GSK3β inhibition, phospho-mutant knock-in, ubiquitination assays and xenografts","pmids":["28619760"],"confidence":"High","gaps":["Exact phospho-degron residues not fully delineated","Breadth across tumor types untested"]},{"year":2017,"claim":"Identified FBXO4 as an additional E3 ligase for MCL-1 influencing chemoresistance.","evidence":"Co-IP, ubiquitination assays, and reciprocal FBXO4 knockdown/overexpression","pmids":["28776569"],"confidence":"Medium","gaps":["Phospho-dependence of FBXO4 recognition not defined","Relationship to Fbw7 not resolved"]},{"year":2017,"claim":"Revealed a nuclear function of MCL-1 as an HR/NHEJ switch via direct binding to Ku, decoupling DNA repair control from apoptosis.","evidence":"CRISPR/shRNA depletion, HR/NHEJ reporters, Co-IP with Ku, BH1/BH3 domain mutants, cell-cycle analysis and xenografts with MI-223","pmids":["29227281"],"confidence":"High","gaps":["How MCL-1 is recruited to chromatin not fully defined","Structural basis of Ku inhibition unresolved"]},{"year":2018,"claim":"Showed that Bim phosphorylation feeds back to control MCL-1 stability and binding specificity, enforcing MCL-1 dependence.","evidence":"Phospho-mimetic/deficient Bim mutants, Co-IP, and MCL-1 stability and viability assays","pmids":["29775995"],"confidence":"Medium","gaps":["Kinase responsible for Bim phosphorylation not defined here","Generalizability beyond the WM model untested"]},{"year":2019,"claim":"Established a direct MCL-1–Akt interaction in which the PEST domain activates Akt, defining a pro-tumorigenic signaling role.","evidence":"CRISPR/shRNA depletion, Co-IP, PEST/PH domain mapping, Akt activity assays, xenografts and the disruptor PH-687","pmids":["31662324"],"confidence":"High","gaps":["Structural model of the PEST/PH interface not solved","Relationship to mitochondrial MCL-1 pool unclear"]},{"year":2020,"claim":"Showed the MCL-1 transmembrane domain self- and hetero-oligomerizes and that cancer mutations in it enhance anti-apoptotic activity.","evidence":"Oligomerization and fractionation assays, Bok TMD heterooligomerization, ER-mitochondria contact analysis, and TMD-variant mutagenesis","pmids":["33093207"],"confidence":"Medium","gaps":["Physiological role of TMD oligomers in normal cells unclear","Structural arrangement of oligomers undefined"]},{"year":2021,"claim":"Identified USP13 as a deubiquitinase that stabilizes MCL-1, adding a stabilizing arm to the turnover network.","evidence":"Co-IP, ubiquitination assays, siRNA, proliferation assays and tissue IHC correlation in cervical cancer","pmids":["33627786"],"confidence":"Medium","gaps":["Binding interface not mapped","Whether USP13 competes with specific E3s untested"]},{"year":2021,"claim":"Established PP2A as the phosphatase that opposes degradative phosphorylation at Ser159/Thr163, completing a kinase-phosphatase switch.","evidence":"Phosphatase siRNA screen, okadaic acid inhibition, phospho-specific blotting and half-life measurements in myeloma","pmids":["33658484"],"confidence":"Medium","gaps":["Direct PP2A–MCL-1 contact not demonstrated","Targeting subunit of PP2A unknown"]},{"year":2022,"claim":"Defined MCL-1 as a transcriptional master regulator of fatty acid oxidation independent of apoptosis, a genuinely separable function.","evidence":"Mcl-1 genetic deletion with metabolomic/proteomic/genomic profiling and glucose-withdrawal lethality in apoptosis-deficient leukemia cells","pmids":["36198266"],"confidence":"High","gaps":["How MCL-1 controls FAO gene transcription mechanistically unknown","Whether this requires a specific subcellular pool unresolved"]},{"year":2022,"claim":"Connected MCL-1 to selective mitophagy through Bnip3 binding and LIR motifs, distinguishing it from suppression of bulk autophagy.","evidence":"Cardiac MCL-1 overexpression, autophagic flux and mitophagy assays, Co-IP with Bnip3, and LIR mutagenesis","pmids":["35563775"],"confidence":"Medium","gaps":["LIR-mediated LC3 binding not directly biophysically confirmed","Crosstalk with apoptotic function unresolved"]},{"year":2022,"claim":"Identified Skp2 as a stabilizing factor that competes with FBW7 to control MCL-1-dependent radioresistance.","evidence":"Co-IP, ubiquitination analysis, Skp2 CRISPR knockout, and xenografts in colorectal cancer","pmids":["35301297"],"confidence":"Medium","gaps":["Mechanism of competition with FBW7 not structurally defined","Whether Skp2 acts catalytically or by occlusion unclear"]},{"year":2022,"claim":"Connected TRAF4 to MCL-1 stability through a TRAF4-Akt-GSK3β axis converging on Ser159 and the deubiquitinase JOSD1.","evidence":"Co-IP of TRAF4 with Akt and MCL-1, GSK3β activity assays, phospho-S159 blotting, TRAF4 KO and xenografts","pmids":["36535926"],"confidence":"Medium","gaps":["Direct JOSD1–MCL-1 interaction interface not mapped","Hierarchy among the many stabilizing factors unresolved"]},{"year":2023,"claim":"Showed that BH3-mimetic MCL-1 inhibitors paradoxically stabilize MCL-1 protein by enhancing USP9x deubiquitination and dissociating partners.","evidence":"Half-life assays, RPPA, Co-IP, in vitro ubiquitination/deubiquitination, DUB inhibitor (WP1130) and modeling","pmids":["36346691"],"confidence":"Medium","gaps":["Mechanism by which inhibitor binding triggers USP9x recruitment unclear","Clinical implications of induced stabilization untested"]},{"year":null,"claim":"How MCL-1's spatially and functionally distinct activities — outer-membrane apoptosis suppression, matrix respiration, nuclear DNA-repair switching, Akt activation and FAO transcription — are coordinated and selectively regulated by its turnover network remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No unifying model links the subcellular pools to specific degradation routes","Structural basis for non-apoptotic interactions (Ku, Akt, Bnip3) undefined","Mechanism of transcriptional FAO control unknown"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140313","term_label":"molecular sequestering activity","supporting_discovery_ids":[0,12]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[0,11,10]},{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[22]}],"localization":[{"term_id":"GO:0005739","term_label":"mitochondrion","supporting_discovery_ids":[4,5]},{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[3,10]}],"pathway":[{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[0,4]},{"term_id":"R-HSA-73894","term_label":"DNA Repair","supporting_discovery_ids":[3,10]},{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[22]},{"term_id":"R-HSA-9612973","term_label":"Autophagy","supporting_discovery_ids":[23]}],"complexes":[],"partners":["BAK","BIM","BAX","KU","AKT","BNIP3","USP13","FBW7"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q07820","full_name":"Induced myeloid leukemia cell differentiation protein Mcl-1","aliases":["Bcl-2-like protein 3","Bcl2-L-3","Bcl-2-related protein EAT/mcl1","mcl1/EAT"],"length_aa":350,"mass_kda":37.3,"function":"Involved in the regulation of apoptosis versus cell survival, and in the maintenance of viability but not of proliferation. Mediates its effects by interactions with a number of other regulators of apoptosis. Isoform 1 inhibits apoptosis. Isoform 2 promotes apoptosis","subcellular_location":"Membrane; Cytoplasm; Mitochondrion; Nucleus, nucleoplasm","url":"https://www.uniprot.org/uniprotkb/Q07820/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":true,"resolved_as":"","url":"https://depmap.org/portal/gene/MCL1","classification":"Common Essential","n_dependent_lines":826,"n_total_lines":1208,"dependency_fraction":0.6837748344370861},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/MCL1","total_profiled":1310},"omim":[{"mim_id":"620976","title":"ZINC FINGER PROTEIN 740; ZNF740","url":"https://www.omim.org/entry/620976"},{"mim_id":"620295","title":"DDB1- AND CUL4-ASSOCIATED FACTOR 10; DCAF10","url":"https://www.omim.org/entry/620295"},{"mim_id":"619936","title":"ANKYRIN REPEAT- AND SOCS BOX-CONTAINING PROTEIN 17; ASB17","url":"https://www.omim.org/entry/619936"},{"mim_id":"615209","title":"MICRO RNA 149; MIR149","url":"https://www.omim.org/entry/615209"},{"mim_id":"612022","title":"OTU DOMAIN-CONTAINING PROTEIN 1; OTUD1","url":"https://www.omim.org/entry/612022"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Enhanced","locations":[{"location":"Mitochondria","reliability":"Enhanced"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in all","driving_tissues":[{"tissue":"bone marrow","ntpm":646.6}],"url":"https://www.proteinatlas.org/search/MCL1"},"hgnc":{"alias_symbol":["BCL2L3","Mcl-1"],"prev_symbol":[]},"alphafold":{"accession":"Q07820","domains":[{"cath_id":"1.10.437.10","chopping":"168-338","consensus_level":"high","plddt":86.5268,"start":168,"end":338}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q07820","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q07820-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q07820-F1-predicted_aligned_error_v6.png","plddt_mean":63.62},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=MCL1","jax_strain_url":"https://www.jax.org/strain/search?query=MCL1"},"sequence":{"accession":"Q07820","fasta_url":"https://rest.uniprot.org/uniprotkb/Q07820.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q07820/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q07820"}},"corpus_meta":[{"pmid":"20540941","id":"PMC_20540941","title":"Mcl-1; the molecular regulation of protein function.","date":"2010","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/20540941","citation_count":453,"is_preprint":false},{"pmid":"9746790","id":"PMC_9746790","title":"Mcl-1 expression in human neutrophils: regulation by cytokines and correlation with cell survival.","date":"1998","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/9746790","citation_count":312,"is_preprint":false},{"pmid":"19099185","id":"PMC_19099185","title":"Mcl-1 is a potential therapeutic target in multiple types of cancer.","date":"2009","source":"Cellular and molecular life sciences : CMLS","url":"https://pubmed.ncbi.nlm.nih.gov/19099185","citation_count":277,"is_preprint":false},{"pmid":"14633975","id":"PMC_14633975","title":"DNA damage response and MCL-1 destruction initiate apoptosis in adenovirus-infected cells.","date":"2003","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/14633975","citation_count":271,"is_preprint":false},{"pmid":"33883020","id":"PMC_33883020","title":"Targeting MCL-1 in cancer: current status and perspectives.","date":"2021","source":"Journal of hematology & oncology","url":"https://pubmed.ncbi.nlm.nih.gov/33883020","citation_count":244,"is_preprint":false},{"pmid":"17062731","id":"PMC_17062731","title":"The antiapoptotic protein Mcl-1 is essential for the survival of neutrophils but not macrophages.","date":"2006","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/17062731","citation_count":239,"is_preprint":false},{"pmid":"23788622","id":"PMC_23788622","title":"Deletion of MCL-1 causes lethal cardiac failure and mitochondrial dysfunction.","date":"2013","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/23788622","citation_count":220,"is_preprint":false},{"pmid":"15474972","id":"PMC_15474972","title":"Mcl-1.","date":"2005","source":"The international journal of biochemistry & cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/15474972","citation_count":209,"is_preprint":false},{"pmid":"23026029","id":"PMC_23026029","title":"Delving deeper: MCL-1's contributions to normal and cancer biology.","date":"2012","source":"Trends in cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/23026029","citation_count":191,"is_preprint":false},{"pmid":"20929728","id":"PMC_20929728","title":"Mcl-1 is essential for germinal center formation and B cell memory.","date":"2010","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/20929728","citation_count":190,"is_preprint":false},{"pmid":"32204955","id":"PMC_32204955","title":"Targeting MCL-1 in hematologic malignancies: Rationale and progress.","date":"2020","source":"Blood reviews","url":"https://pubmed.ncbi.nlm.nih.gov/32204955","citation_count":169,"is_preprint":false},{"pmid":"18550749","id":"PMC_18550749","title":"Mcl-1 is a key regulator of apoptosis during CNS development and after DNA damage.","date":"2008","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/18550749","citation_count":165,"is_preprint":false},{"pmid":"21851287","id":"PMC_21851287","title":"Targeting Mcl-1 for the therapy of cancer.","date":"2011","source":"Expert opinion on investigational drugs","url":"https://pubmed.ncbi.nlm.nih.gov/21851287","citation_count":160,"is_preprint":false},{"pmid":"24814761","id":"PMC_24814761","title":"Mcl-1 ubiquitination: unique regulation of an essential survival protein.","date":"2014","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/24814761","citation_count":156,"is_preprint":false},{"pmid":"25172548","id":"PMC_25172548","title":"Small molecule Mcl-1 inhibitors for the treatment of cancer.","date":"2014","source":"Pharmacology & therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/25172548","citation_count":140,"is_preprint":false},{"pmid":"15217829","id":"PMC_15217829","title":"VEGF induces Mcl-1 up-regulation and protects multiple myeloma cells against apoptosis.","date":"2004","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/15217829","citation_count":131,"is_preprint":false},{"pmid":"31907390","id":"PMC_31907390","title":"Saga of Mcl-1: regulation from transcription to degradation.","date":"2020","source":"Cell death and differentiation","url":"https://pubmed.ncbi.nlm.nih.gov/31907390","citation_count":128,"is_preprint":false},{"pmid":"15467463","id":"PMC_15467463","title":"Mcl-1 regulation and its role in multiple myeloma.","date":"2004","source":"Cell cycle (Georgetown, Tex.)","url":"https://pubmed.ncbi.nlm.nih.gov/15467463","citation_count":120,"is_preprint":false},{"pmid":"19372583","id":"PMC_19372583","title":"Mcl-1 is required for melanoma cell resistance to anoikis.","date":"2009","source":"Molecular cancer research : MCR","url":"https://pubmed.ncbi.nlm.nih.gov/19372583","citation_count":114,"is_preprint":false},{"pmid":"26538029","id":"PMC_26538029","title":"Mcl-1 involvement in mitochondrial dynamics is associated with apoptotic cell death.","date":"2015","source":"Molecular biology of the cell","url":"https://pubmed.ncbi.nlm.nih.gov/26538029","citation_count":113,"is_preprint":false},{"pmid":"20385764","id":"PMC_20385764","title":"Ubiquitin-independent degradation of antiapoptotic MCL-1.","date":"2010","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/20385764","citation_count":107,"is_preprint":false},{"pmid":"30425521","id":"PMC_30425521","title":"MCL-1 inhibition in cancer treatment.","date":"2018","source":"OncoTargets and therapy","url":"https://pubmed.ncbi.nlm.nih.gov/30425521","citation_count":106,"is_preprint":false},{"pmid":"30790641","id":"PMC_30790641","title":"Recent advances in the development of Mcl-1 inhibitors for cancer therapy.","date":"2019","source":"Pharmacology & therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/30790641","citation_count":105,"is_preprint":false},{"pmid":"35449130","id":"PMC_35449130","title":"Single-cell transcriptomics identifies Mcl-1 as a target for senolytic therapy in cancer.","date":"2022","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/35449130","citation_count":99,"is_preprint":false},{"pmid":"18381408","id":"PMC_18381408","title":"Mcl-1: a gateway to TRAIL sensitization.","date":"2008","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/18381408","citation_count":98,"is_preprint":false},{"pmid":"20971952","id":"PMC_20971952","title":"Homoharringtonine reduced Mcl-1 expression and induced apoptosis in chronic lymphocytic leukemia.","date":"2010","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/20971952","citation_count":98,"is_preprint":false},{"pmid":"16456709","id":"PMC_16456709","title":"Mcl-1: a highly regulated cell death and survival controller.","date":"2006","source":"Journal of biomedical science","url":"https://pubmed.ncbi.nlm.nih.gov/16456709","citation_count":90,"is_preprint":false},{"pmid":"18006817","id":"PMC_18006817","title":"Anoikis, initiated by Mcl-1 degradation and Bim induction, is deregulated during oncogenesis.","date":"2007","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/18006817","citation_count":86,"is_preprint":false},{"pmid":"33146521","id":"PMC_33146521","title":"Discovery of S64315, a Potent and Selective Mcl-1 Inhibitor.","date":"2020","source":"Journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/33146521","citation_count":85,"is_preprint":false},{"pmid":"15157168","id":"PMC_15157168","title":"Regulation of neutrophil apoptosis by Mcl-1.","date":"2004","source":"Biochemical Society transactions","url":"https://pubmed.ncbi.nlm.nih.gov/15157168","citation_count":85,"is_preprint":false},{"pmid":"31030977","id":"PMC_31030977","title":"Molecular Comprehension of Mcl-1: From Gene Structure to Cancer Therapy.","date":"2019","source":"Trends in cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/31030977","citation_count":78,"is_preprint":false},{"pmid":"23284704","id":"PMC_23284704","title":"Regulation of Mcl-1 by SRSF1 and SRSF5 in cancer cells.","date":"2012","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/23284704","citation_count":78,"is_preprint":false},{"pmid":"23551751","id":"PMC_23551751","title":"MiR-139 inhibits Mcl-1 expression and potentiates TMZ-induced apoptosis in glioma.","date":"2013","source":"CNS neuroscience & therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/23551751","citation_count":78,"is_preprint":false},{"pmid":"21608150","id":"PMC_21608150","title":"Mcl-1 ubiquitination and destruction.","date":"2011","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/21608150","citation_count":74,"is_preprint":false},{"pmid":"22125448","id":"PMC_22125448","title":"Regulation of neutrophil survival/apoptosis by Mcl-1.","date":"2011","source":"TheScientificWorldJournal","url":"https://pubmed.ncbi.nlm.nih.gov/22125448","citation_count":72,"is_preprint":false},{"pmid":"12475993","id":"PMC_12475993","title":"Tankyrase 1 interacts with Mcl-1 proteins and inhibits their regulation of apoptosis.","date":"2002","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12475993","citation_count":68,"is_preprint":false},{"pmid":"25871384","id":"PMC_25871384","title":"Multiple myeloma induces Mcl-1 expression and survival of myeloid-derived suppressor cells.","date":"2015","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/25871384","citation_count":64,"is_preprint":false},{"pmid":"26769847","id":"PMC_26769847","title":"Mcl-1 dynamics influence mitotic slippage and death in mitosis.","date":"2016","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/26769847","citation_count":63,"is_preprint":false},{"pmid":"33333396","id":"PMC_33333396","title":"Development of Mcl-1 inhibitors for cancer therapy.","date":"2020","source":"European journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/33333396","citation_count":62,"is_preprint":false},{"pmid":"12941295","id":"PMC_12941295","title":"Transcriptional and translational control of Mcl-1 during apoptosis.","date":"2003","source":"Archives of biochemistry and biophysics","url":"https://pubmed.ncbi.nlm.nih.gov/12941295","citation_count":62,"is_preprint":false},{"pmid":"32724460","id":"PMC_32724460","title":"Mcl-1 inhibition overcomes intrinsic and acquired regorafenib resistance in colorectal cancer.","date":"2020","source":"Theranostics","url":"https://pubmed.ncbi.nlm.nih.gov/32724460","citation_count":60,"is_preprint":false},{"pmid":"31580668","id":"PMC_31580668","title":"Hot-Spots of Mcl-1 Protein.","date":"2019","source":"Journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/31580668","citation_count":59,"is_preprint":false},{"pmid":"20647761","id":"PMC_20647761","title":"MCL-1 localizes to sites of DNA damage and regulates DNA damage response.","date":"2010","source":"Cell cycle (Georgetown, Tex.)","url":"https://pubmed.ncbi.nlm.nih.gov/20647761","citation_count":59,"is_preprint":false},{"pmid":"28619760","id":"PMC_28619760","title":"FBW7-Dependent Mcl-1 Degradation Mediates the Anticancer Effect of Hsp90 Inhibitors.","date":"2017","source":"Molecular cancer therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/28619760","citation_count":58,"is_preprint":false},{"pmid":"37601693","id":"PMC_37601693","title":"Targeting MCL-1 protein to treat cancer: opportunities and challenges.","date":"2023","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/37601693","citation_count":56,"is_preprint":false},{"pmid":"27893461","id":"PMC_27893461","title":"Dual modulation of MCL-1 and mTOR determines the response to sunitinib.","date":"2016","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/27893461","citation_count":56,"is_preprint":false},{"pmid":"29227281","id":"PMC_29227281","title":"Targeting Mcl-1 enhances DNA replication stress sensitivity to cancer therapy.","date":"2017","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/29227281","citation_count":54,"is_preprint":false},{"pmid":"27234233","id":"PMC_27234233","title":"Intersection of mitochondrial fission and fusion machinery with apoptotic pathways: Role of Mcl-1.","date":"2016","source":"Biology of the cell","url":"https://pubmed.ncbi.nlm.nih.gov/27234233","citation_count":54,"is_preprint":false},{"pmid":"26009874","id":"PMC_26009874","title":"Mcl-1 is an important therapeutic target for oral squamous cell carcinomas.","date":"2015","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/26009874","citation_count":53,"is_preprint":false},{"pmid":"27159560","id":"PMC_27159560","title":"Allosteric inhibition of antiapoptotic MCL-1.","date":"2016","source":"Nature structural & molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/27159560","citation_count":52,"is_preprint":false},{"pmid":"32913197","id":"PMC_32913197","title":"MCL-1 gains occur with high frequency in lung adenocarcinoma and can be targeted therapeutically.","date":"2020","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/32913197","citation_count":51,"is_preprint":false},{"pmid":"29407973","id":"PMC_29407973","title":"Small-molecule Mcl-1 inhibitors: Emerging anti-tumor agents.","date":"2018","source":"European journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/29407973","citation_count":51,"is_preprint":false},{"pmid":"31566022","id":"PMC_31566022","title":"MCL-1 inhibitors - where are we now (2019)?","date":"2019","source":"Expert opinion on therapeutic patents","url":"https://pubmed.ncbi.nlm.nih.gov/31566022","citation_count":49,"is_preprint":false},{"pmid":"31937611","id":"PMC_31937611","title":"AMG-176, an Mcl-1 Antagonist, Shows Preclinical Efficacy in Chronic Lymphocytic Leukemia.","date":"2020","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/31937611","citation_count":49,"is_preprint":false},{"pmid":"32659848","id":"PMC_32659848","title":"Pairing MCL-1 inhibition with venetoclax improves therapeutic efficiency of BH3-mimetics in AML.","date":"2020","source":"European journal of haematology","url":"https://pubmed.ncbi.nlm.nih.gov/32659848","citation_count":46,"is_preprint":false},{"pmid":"29797573","id":"PMC_29797573","title":"Mcl-1 targeting could be an intriguing perspective to cure cancer.","date":"2018","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/29797573","citation_count":45,"is_preprint":false},{"pmid":"33627786","id":"PMC_33627786","title":"The deubiquitinase (DUB) USP13 promotes Mcl-1 stabilisation in cervical cancer.","date":"2021","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/33627786","citation_count":45,"is_preprint":false},{"pmid":"24811082","id":"PMC_24811082","title":"Bak and Mcl-1 are essential for Temozolomide induced cell death in human glioma.","date":"2014","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/24811082","citation_count":44,"is_preprint":false},{"pmid":"27744724","id":"PMC_27744724","title":"Mcl-1 inhibitors: a patent review.","date":"2016","source":"Expert opinion on therapeutic patents","url":"https://pubmed.ncbi.nlm.nih.gov/27744724","citation_count":42,"is_preprint":false},{"pmid":"35301297","id":"PMC_35301297","title":"Skp2 stabilizes Mcl-1 and confers radioresistance in colorectal cancer.","date":"2022","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/35301297","citation_count":42,"is_preprint":false},{"pmid":"30468106","id":"PMC_30468106","title":"Regulation of Mcl-1 alternative splicing by hnRNP F, H1 and K in breast cancer cells.","date":"2018","source":"RNA biology","url":"https://pubmed.ncbi.nlm.nih.gov/30468106","citation_count":41,"is_preprint":false},{"pmid":"22277751","id":"PMC_22277751","title":"Caveolin-1 regulates Mcl-1 stability and anoikis in lung carcinoma cells.","date":"2012","source":"American journal of physiology. Cell physiology","url":"https://pubmed.ncbi.nlm.nih.gov/22277751","citation_count":39,"is_preprint":false},{"pmid":"33785871","id":"PMC_33785871","title":"Breast cancer dependence on MCL-1 is due to its canonical anti-apoptotic function.","date":"2021","source":"Cell death and differentiation","url":"https://pubmed.ncbi.nlm.nih.gov/33785871","citation_count":39,"is_preprint":false},{"pmid":"33093207","id":"PMC_33093207","title":"Mcl-1 and Bok transmembrane domains: Unexpected players in the modulation of apoptosis.","date":"2020","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/33093207","citation_count":37,"is_preprint":false},{"pmid":"19734538","id":"PMC_19734538","title":"Mcl-1 degradation during hepatocyte lipoapoptosis.","date":"2009","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/19734538","citation_count":37,"is_preprint":false},{"pmid":"21674276","id":"PMC_21674276","title":"The expression of Mcl-1 in human cervical cancer and its clinical significance.","date":"2011","source":"Medical oncology (Northwood, London, England)","url":"https://pubmed.ncbi.nlm.nih.gov/21674276","citation_count":37,"is_preprint":false},{"pmid":"27479182","id":"PMC_27479182","title":"Survival control of malignant lymphocytes by anti-apoptotic MCL-1.","date":"2016","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/27479182","citation_count":36,"is_preprint":false},{"pmid":"31921615","id":"PMC_31921615","title":"Transcriptional Silencing of MCL-1 Through Cyclin-Dependent Kinase Inhibition in Acute Myeloid Leukemia.","date":"2019","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/31921615","citation_count":35,"is_preprint":false},{"pmid":"21953453","id":"PMC_21953453","title":"Identification of a novel Mcl-1 protein binding motif.","date":"2011","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/21953453","citation_count":34,"is_preprint":false},{"pmid":"32569380","id":"PMC_32569380","title":"Cotargeting BCL-2 and MCL-1 in high-risk B-ALL.","date":"2020","source":"Blood advances","url":"https://pubmed.ncbi.nlm.nih.gov/32569380","citation_count":33,"is_preprint":false},{"pmid":"28776569","id":"PMC_28776569","title":"FBXO4 inhibits lung cancer cell survival by targeting Mcl-1 for degradation.","date":"2017","source":"Cancer gene therapy","url":"https://pubmed.ncbi.nlm.nih.gov/28776569","citation_count":33,"is_preprint":false},{"pmid":"32794745","id":"PMC_32794745","title":"Discovery of a Copper-Based Mcl-1 Inhibitor as an Effective Antitumor Agent.","date":"2020","source":"Journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/32794745","citation_count":32,"is_preprint":false},{"pmid":"28350964","id":"PMC_28350964","title":"Promoting Vaginal Distribution of E7 and MCL-1 siRNA-Silencing Nanoparticles for Cervical Cancer Treatment.","date":"2017","source":"Molecular pharmaceutics","url":"https://pubmed.ncbi.nlm.nih.gov/28350964","citation_count":32,"is_preprint":false},{"pmid":"34349655","id":"PMC_34349655","title":"Mcl-1 Inhibition: Managing Malignancy in Multiple Myeloma.","date":"2021","source":"Frontiers in pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/34349655","citation_count":31,"is_preprint":false},{"pmid":"19037233","id":"PMC_19037233","title":"Mcl-1 functions as major epidermal survival protein required for proper keratinocyte differentiation.","date":"2009","source":"The Journal of investigative dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/19037233","citation_count":31,"is_preprint":false},{"pmid":"25929430","id":"PMC_25929430","title":"Mcl-1 is vital for neutrophil survival.","date":"2015","source":"Immunologic research","url":"https://pubmed.ncbi.nlm.nih.gov/25929430","citation_count":30,"is_preprint":false},{"pmid":"31662324","id":"PMC_31662324","title":"Mcl-1 Interacts with Akt to Promote Lung Cancer Progression.","date":"2019","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/31662324","citation_count":30,"is_preprint":false},{"pmid":"25950485","id":"PMC_25950485","title":"Mcl-1 is a key regulator of the ovarian reserve.","date":"2015","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/25950485","citation_count":30,"is_preprint":false},{"pmid":"23872918","id":"PMC_23872918","title":"Notch signaling regulates expression of Mcl-1 and apoptosis in PPD-treated macrophages.","date":"2013","source":"Cellular & molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/23872918","citation_count":29,"is_preprint":false},{"pmid":"36198266","id":"PMC_36198266","title":"MCL-1 is a master regulator of cancer dependency on fatty acid oxidation.","date":"2022","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/36198266","citation_count":28,"is_preprint":false},{"pmid":"35349392","id":"PMC_35349392","title":"MCL-1 is a clinically targetable vulnerability in breast cancer.","date":"2022","source":"Cell cycle (Georgetown, Tex.)","url":"https://pubmed.ncbi.nlm.nih.gov/35349392","citation_count":25,"is_preprint":false},{"pmid":"35563775","id":"PMC_35563775","title":"Mcl-1 Differentially Regulates Autophagy in Response to Changes in Energy Status and Mitochondrial Damage.","date":"2022","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/35563775","citation_count":25,"is_preprint":false},{"pmid":"31467029","id":"PMC_31467029","title":"CDK5 Inhibitor Downregulates Mcl-1 and Sensitizes Pancreatic Cancer Cell Lines to Navitoclax.","date":"2019","source":"Molecular pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/31467029","citation_count":25,"is_preprint":false},{"pmid":"29775995","id":"PMC_29775995","title":"Phosphorylation alters Bim-mediated Mcl-1 stabilization and priming.","date":"2018","source":"The FEBS journal","url":"https://pubmed.ncbi.nlm.nih.gov/29775995","citation_count":24,"is_preprint":false},{"pmid":"32124438","id":"PMC_32124438","title":"Sphingosine kinase-2 is overexpressed in large granular lymphocyte leukaemia and promotes survival through Mcl-1.","date":"2020","source":"British journal of haematology","url":"https://pubmed.ncbi.nlm.nih.gov/32124438","citation_count":24,"is_preprint":false},{"pmid":"26118775","id":"PMC_26118775","title":"AML sensitivity to YM155 is modulated through AKT and Mcl-1.","date":"2015","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/26118775","citation_count":23,"is_preprint":false},{"pmid":"24481815","id":"PMC_24481815","title":"STAT3 and MCL-1 associate to cause a mesenchymal epithelial transition.","date":"2014","source":"Journal of cell science","url":"https://pubmed.ncbi.nlm.nih.gov/24481815","citation_count":22,"is_preprint":false},{"pmid":"21247487","id":"PMC_21247487","title":"Bim and Mcl-1 exert key roles in regulating JAK2V617F cell survival.","date":"2011","source":"BMC cancer","url":"https://pubmed.ncbi.nlm.nih.gov/21247487","citation_count":22,"is_preprint":false},{"pmid":"27246906","id":"PMC_27246906","title":"Dual inhibition of Mcl-1 by the combination of carfilzomib and TG02 in multiple myeloma.","date":"2016","source":"Cancer biology & therapy","url":"https://pubmed.ncbi.nlm.nih.gov/27246906","citation_count":22,"is_preprint":false},{"pmid":"36346691","id":"PMC_36346691","title":"Mechanisms of MCL-1 Protein Stability Induced by MCL-1 Antagonists in B-Cell Malignancies.","date":"2023","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/36346691","citation_count":21,"is_preprint":false},{"pmid":"36535926","id":"PMC_36535926","title":"Stabilization of MCL-1 by E3 ligase TRAF4 confers radioresistance.","date":"2022","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/36535926","citation_count":21,"is_preprint":false},{"pmid":"33241675","id":"PMC_33241675","title":"Inhibition of the anti-apoptotic protein MCL-1 severely suppresses human hematopoiesis.","date":"2021","source":"Haematologica","url":"https://pubmed.ncbi.nlm.nih.gov/33241675","citation_count":21,"is_preprint":false},{"pmid":"33512417","id":"PMC_33512417","title":"Requirement for antiapoptotic MCL-1 during early erythropoiesis.","date":"2021","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/33512417","citation_count":20,"is_preprint":false},{"pmid":"28667119","id":"PMC_28667119","title":"MCL-1 Is a Key Antiapoptotic Protein in Human and Rodent Pancreatic β-Cells.","date":"2017","source":"Diabetes","url":"https://pubmed.ncbi.nlm.nih.gov/28667119","citation_count":20,"is_preprint":false},{"pmid":"30201826","id":"PMC_30201826","title":"Repurposing of mTOR Complex Inhibitors Attenuates MCL-1 and Sensitizes to PARP Inhibition.","date":"2018","source":"Molecular cancer research : MCR","url":"https://pubmed.ncbi.nlm.nih.gov/30201826","citation_count":20,"is_preprint":false},{"pmid":"25756510","id":"PMC_25756510","title":"EGFR signaling defines Mcl⁻1 survival dependency in neuroblastoma.","date":"2015","source":"Cancer biology & therapy","url":"https://pubmed.ncbi.nlm.nih.gov/25756510","citation_count":20,"is_preprint":false},{"pmid":"33658484","id":"PMC_33658484","title":"Phosphatase PP2A enhances MCL-1 protein half-life in multiple myeloma cells.","date":"2021","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/33658484","citation_count":18,"is_preprint":false},{"pmid":"31735913","id":"PMC_31735913","title":"MCL-1 antagonism enhances the anti-invasive effects of dasatinib in pancreatic adenocarcinoma.","date":"2019","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/31735913","citation_count":18,"is_preprint":false},{"pmid":"33763603","id":"PMC_33763603","title":"Photocatalytic proximity labelling of MCL-1 by a BH3 ligand.","date":"2019","source":"Communications chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/33763603","citation_count":18,"is_preprint":false},{"pmid":"28520795","id":"PMC_28520795","title":"BIRC6 mediates imatinib resistance independently of Mcl-1.","date":"2017","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/28520795","citation_count":18,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":45565,"output_tokens":9231,"usd":0.13758,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":19416,"output_tokens":7895,"usd":0.147228,"stage2_stop_reason":"end_turn"},"total_usd":0.284808,"stage1_batch_id":"msgbatch_01BbTCMyrRPyhtEq6b1MdwCN","stage2_batch_id":"msgbatch_011dEed5bbxYvTAaQWKJevxu","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2003,\n      \"finding\": \"In uninfected cells, BAK is complexed with MCL-1. Upon adenovirus E1A expression, MCL-1 is specifically down-regulated through protein destabilization and mRNA loss, releasing BAK from the MCL-1-BAK complex. Loss of MCL-1 was required to initiate apoptosis, as restoration of MCL-1 expression rescued infected cells from E1A-induced apoptosis. MCL-1 thus maintains BAK in an inactive state.\",\n      \"method\": \"Co-immunoprecipitation, Western blotting, rescue expression experiments in adenovirus-infected cells\",\n      \"journal\": \"Genes & development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal Co-IP establishing BAK complex, combined with rescue experiments demonstrating functional requirement; multiple orthogonal methods in one study\",\n      \"pmids\": [\"14633975\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"Tankyrase 1 physically interacts with both MCL-1L and MCL-1S isoforms via its first 10 ankyrin repeats binding to a 25-amino-acid stretch in the N-terminus of MCL-1. Overexpression of tankyrase 1 antagonizes MCL-1L-mediated cell survival and MCL-1S-induced cell death, and decreases MCL-1 protein levels. No ADP-ribosylation of MCL-1 was detected; instead, MCL-1 overexpression suppresses ADP-ribosylation of the tankyrase substrate TRF1.\",\n      \"method\": \"Yeast two-hybrid screening, co-immunoprecipitation in mammalian cells, truncation mutant analysis, overexpression functional assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — yeast two-hybrid plus Co-IP plus functional assays, single lab, multiple orthogonal methods\",\n      \"pmids\": [\"12475993\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"MCL-1 degradation can occur independently of ubiquitination. An MCL-1 mutant lacking all lysine residues (MCL-1(KR)) that cannot be ubiquitinated is degraded at a rate similar to wild-type MCL-1 under both basal and stressed conditions. Unmodified, in vitro-translated MCL-1 is degraded by the 20S proteasome in a cell-free system.\",\n      \"method\": \"Ubiquitination-deficient MCL-1(KR) mutant expression, blocking E1 ubiquitin-activating enzyme, in vitro 20S proteasome degradation assay, primary lymphocyte experiments\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro proteasome reconstitution assay combined with mutagenesis (KR mutant) and E1 inhibition, multiple orthogonal methods in single study\",\n      \"pmids\": [\"20385764\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"MCL-1 localizes to sites of DNA double-strand breaks (co-localizes with γ-H2AX and NBS1 by immunoprecipitation and immunofluorescence, and is directly recruited adjacent to DSB sites). MCL-1-deficient MEFs show delayed Chk1 phosphorylation and delayed γ-H2AX appearance after etoposide treatment. Loss of MCL-1 results in greater accumulation of chromosomal abnormalities after repeated etoposide treatment, indicating a role in DNA damage checkpoint response and genome integrity.\",\n      \"method\": \"Co-immunoprecipitation with γ-H2AX and NBS1, immunofluorescence co-staining, site-specific DSB recruitment assay, comparison of Mcl-1−/− vs. wild-type MEFs, chromosomal aberration analysis\",\n      \"journal\": \"Cell cycle (Georgetown, Tex.)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct DSB recruitment assay plus Co-IP plus KO MEF functional analysis; single lab, multiple orthogonal methods\",\n      \"pmids\": [\"20647761\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Cardiac-specific ablation of Mcl-1 results in fatal dilated cardiomyopathy with loss of cardiac contractility, abnormal mitochondrial ultrastructure, and defective mitochondrial respiration. Genetic co-deletion of Bax and Bak largely rescues lethality and cardiac function, but mitochondrial ultrastructural abnormalities and deficient respiration persist, indicating that MCL-1 has a function in mitochondrial physiology beyond apoptosis suppression.\",\n      \"method\": \"Conditional cardiac-specific Mcl-1 knockout mice, genetic epistasis with Bax/Bak double knockout, electron microscopy of mitochondrial ultrastructure, mitochondrial respiration assays\",\n      \"journal\": \"Genes & development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — conditional KO with genetic epistasis (Bax/Bak rescue), electron microscopy, and respiration assays; multiple orthogonal methods demonstrating separable apoptotic vs. mitochondrial functions\",\n      \"pmids\": [\"23788622\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"MCL-1's antiapoptotic activity is restricted to the outer mitochondrial membrane (OMM), whereas its function in maintaining normal mitochondrial morphology and energy production requires localization to the matrix. These two functions depend on separate mitochondrial sublocalizations.\",\n      \"method\": \"Subcellular fractionation, functional studies with localization variants (review synthesizing multiple experimental studies)\",\n      \"journal\": \"Trends in cell biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — review synthesizing direct localization and functional experiments across multiple studies; localization tied to distinct functional consequences\",\n      \"pmids\": [\"23026029\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"SCF-Fbw7 E3 ubiquitin ligase mediates MCL-1 ubiquitination and proteasomal degradation in a GSK3 phosphorylation-dependent manner. Loss of Fbw7 tumor suppressor results in MCL-1 overexpression and resistance to ABT-737. Reconstitution of Fbw7 or depletion of MCL-1 in Fbw7-deficient cells restores ABT-737 sensitivity.\",\n      \"method\": \"Ubiquitination assays, GSK3 inhibition experiments, Fbw7 reconstitution, Mcl-1 siRNA knockdown, cell viability assays in T-ALL cell lines\",\n      \"journal\": \"Oncotarget\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ubiquitination assays plus rescue experiments; single lab, multiple approaches\",\n      \"pmids\": [\"21608150\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Hsp90 inhibition promotes GSK3β-dependent phosphorylation of MCL-1, which then binds to FBW7 and undergoes ubiquitination and proteasomal degradation. Blocking MCL-1 phosphorylation by genetic knock-in abrogates its degradation and confers resistance to Hsp90 inhibitors in vitro and in vivo.\",\n      \"method\": \"GSK3β inhibitor experiments, Mcl-1 phospho-mutant knock-in, ubiquitination assays, FBW7 mutation analysis in colorectal cancer cells, in vivo xenograft models\",\n      \"journal\": \"Molecular cancer therapeutics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — genetic knock-in of phospho-mutant plus ubiquitination assays plus in vivo validation; multiple orthogonal methods establishing mechanism\",\n      \"pmids\": [\"28619760\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"MCL-1 is rapidly degraded in hepatocytes in response to palmitate via a PKCθ-dependent, proteasome-dependent pathway. PKCθ promotes phosphorylation of MCL-1 at Ser159. An MCL-1 S159A mutant is resistant to palmitate-induced degradation and improves cell survival. Overexpression of a ubiquitin-resistant MCL-1 mutant attenuates palmitate-induced lipoapoptosis.\",\n      \"method\": \"Proteasome inhibitor experiments, novel PKC inhibitor (rottlerin), shRNA knockdown of PKCθ, PKCθ genetic deletion in primary hepatocytes, phospho-immunoblot of MCL-1 Ser159, MCL-1 S159A mutant expression, ubiquitin-resistant Mcl-1 mutant overexpression\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — site-directed mutagenesis (S159A) plus genetic KO plus pharmacological inhibition, multiple orthogonal approaches in single study\",\n      \"pmids\": [\"19734538\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"Cell detachment from ECM rapidly degrades MCL-1 via a GSK-3β-dependent proteasomal pathway and transcriptionally up-regulates Bim. MCL-1 degradation in the presence of Bim is sufficient to induce anoikis. Dysregulation of this MCL-1 degradation/Bim induction axis contributes to anoikis resistance in metastatic cancer cells.\",\n      \"method\": \"GSK-3β inhibition, proteasome inhibitor experiments, knockdown of MCL-1 and Bim, comparison of non-metastatic vs. metastatic cell lines, in vivo metastasis assay\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pharmacological pathway manipulation plus siRNA knockdown plus in vivo validation; single lab, multiple complementary approaches\",\n      \"pmids\": [\"18006817\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"MCL-1 acts as a functional switch between homologous recombination (HR) and non-homologous end-joining (NHEJ) DNA repair pathways. MCL-1 depletion reduces HR and enhances NHEJ, while MCL-1 overexpression increases HR over NHEJ. MCL-1 directly interacts with the Ku protein complex via its BH1 and BH3 domains to inhibit Ku-mediated NHEJ. MCL-1 also promotes DNA resection by the Mre11 complex. MCL-1 expression peaks in S/G2 phase in a cell-cycle-regulated manner during HR.\",\n      \"method\": \"CRISPR/Cas9 and shRNA depletion, HR/NHEJ reporter assays, co-immunoprecipitation of MCL-1 with Ku complex, domain deletion mutants (BH1, BH3), cell cycle analysis, in vivo lung cancer xenograft experiments with small molecule MI-223\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — direct interaction via Co-IP with domain mapping, functional HR/NHEJ assays, KO/KD, and in vivo validation; multiple orthogonal methods in single rigorous study\",\n      \"pmids\": [\"29227281\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"MCL-1 directly interacts with Akt via its PEST domain binding to the pleckstrin homology (PH) domain of Akt. This Mcl-1/PH domain interaction disrupts intramolecular PH/kinase domain interactions of Akt, thereby activating Akt. Depletion of MCL-1 by CRISPR/Cas9 or shRNA significantly decreases Akt activity and suppresses lung cancer cell growth in vitro and in xenografts.\",\n      \"method\": \"CRISPR/Cas9 and shRNA depletion of MCL-1, co-immunoprecipitation of MCL-1 with Akt, domain-specific interaction mapping (PEST domain vs. PH domain), Akt activity measurements, xenograft models, small molecule PH-687 disruption of MCL-1/Akt interaction\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — direct interaction via Co-IP with domain mapping, CRISPR KO, functional Akt activity assay, and in vivo xenograft validation; multiple orthogonal methods\",\n      \"pmids\": [\"31662324\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"A cysteine residue (C286) at a site distant from the BH3-binding groove of MCL-1 serves as an allosteric regulatory site. Covalent small-molecule modification of C286 impairs the BH3 binding capacity of MCL-1 and its suppression of BAX, as recapitulated by C286W mutagenic mimicry in vitro and in mouse cells.\",\n      \"method\": \"Covalent small-molecule modification, C286W mutagenesis, structure-function analysis, in vitro BH3 binding assay, BAX suppression assay in mouse cells, hydrogen-deuterium exchange mass spectrometry\",\n      \"journal\": \"Nature structural & molecular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — structure-function analysis with site-directed mutagenesis, in vitro functional assay, and cell-based validation; multiple orthogonal approaches in single rigorous study\",\n      \"pmids\": [\"27159560\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"SRSF1 and SRSF5 RNA-binding proteins regulate alternative splicing of MCL-1 pre-mRNA. Knockdown of SRSF1 shifts splicing toward pro-apoptotic MCL-1S in breast cancer cells. SRSF1 also affects MCL-1 protein stability and translation in a cell-context-dependent manner.\",\n      \"method\": \"siRNA knockdown of SRSF1 and SRSF5, RT-PCR splicing analysis, Western blotting in breast cancer and choriocarcinoma cell lines\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — RNAi knockdown of splicing factors with direct splicing readout; single lab, two orthogonal methods (splicing and protein level)\",\n      \"pmids\": [\"23284704\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"hnRNP F, H1, and K RNA-binding proteins regulate alternative splicing of MCL-1 pre-mRNA. siRNA knockdown of hnRNP K and the hnRNP F/H family switches splicing toward pro-apoptotic MCL-1S. Specific binding sites for these factors were identified by RNA immunoprecipitation using a MCL-1 minigene construct. Triple knockdown achieves up to 30-fold increase in MCL-1S levels and activates the mitochondrial cell death pathway.\",\n      \"method\": \"siRNA knockdown, RT-PCR splicing analysis, RNA immunoprecipitation, MCL-1 minigene construct, apoptosis assays\",\n      \"journal\": \"RNA biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — RNA immunoprecipitation plus minigene construct plus functional apoptosis readout; single lab, multiple orthogonal methods\",\n      \"pmids\": [\"30468106\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"MCL-1 involvement in mitochondrial dynamics is mediated through its two isoforms: increased MCL-1S/L ratio (promoted by splice-switching antisense oligonucleotides) induces mitochondrial hyperfusion in a Drp1-dependent manner and increases mitochondrial calcium accumulation. The balance between MCL-1L and MCL-1S isoforms regulates mitochondrial fusion/fission machinery.\",\n      \"method\": \"Splice-switching antisense oligonucleotides, measurement of mitochondrial morphology, mitochondrial calcium accumulation assays, Drp1-dependence analysis\",\n      \"journal\": \"Molecular biology of the cell\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct manipulation of isoform ratio via ASOs with functional mitochondrial readout; single lab, multiple measurements\",\n      \"pmids\": [\"26538029\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"The deubiquitinase USP13 binds to, deubiquitinates, and stabilizes MCL-1 in cervical cancer cells. Depletion of USP13 reduces MCL-1 protein levels and inhibits cell proliferation. USP13 and MCL-1 protein levels correlate in cervical cancer tissue.\",\n      \"method\": \"Co-immunoprecipitation of USP13 with MCL-1, ubiquitination assays, siRNA knockdown, proliferation assays, IHC correlation in tissue\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP plus ubiquitination assay plus functional KD; single lab, multiple orthogonal methods\",\n      \"pmids\": [\"33627786\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Skp2 stabilizes MCL-1 by competing with the E3 ligase FBW7-mediated MCL-1 ubiquitination. Depletion of Skp2 enhances FBW7-mediated MCL-1 ubiquitination and degradation, increasing irradiation-induced apoptosis. The Skp2/MCL-1 axis controls radioresistance in colorectal cancer.\",\n      \"method\": \"Co-immunoprecipitation, ubiquitination analysis, CRISPR-Cas9 Skp2 knockout, Western blotting, xenograft experiments, flow cytometry\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP plus ubiquitination assay plus CRISPR KO plus in vivo validation; single lab, multiple complementary approaches\",\n      \"pmids\": [\"35301297\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Stabilization of MCL-1 by E3 ligase TRAF4 occurs through a TRAF4-Akt-GSK3β signaling axis. TRAF4 promotes Akt K63-mediated ubiquitination and activation; TRAF4 knockout inhibits Akt phosphorylation and upregulates GSK3β activity, leading to increased MCL-1 S159 phosphorylation that disrupts MCL-1 interaction with deubiquitinase JOSD1, thereby promoting MCL-1 ubiquitination and degradation.\",\n      \"method\": \"Co-immunoprecipitation of TRAF4 with Akt and MCL-1, ubiquitination analysis, GSK3β activity assays, phospho-specific Western blotting (MCL-1 S159), TRAF4 knockout, xenograft experiments\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP plus phosphorylation mapping plus KO experiments; single lab, multiple orthogonal methods\",\n      \"pmids\": [\"36535926\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"PP2A phosphatase stabilizes MCL-1 in multiple myeloma cells by dephosphorylating MCL-1 at Ser159 and/or Thr163. PP2A inhibition by okadaic acid increases MCL-1 phosphorylation at these sites and destabilizes MCL-1. The MCL-1 half-life in MM is regulated by counteracting functions of JNK kinase and PP2A phosphatase.\",\n      \"method\": \"Phosphatase siRNA screen, PP2A inhibitor (okadaic acid), phospho-specific Western blotting, combined kinase/phosphatase inhibitor experiments, MCL-1 half-life measurements\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — siRNA screen plus pharmacological validation plus phospho-site specific analysis; single lab, multiple orthogonal methods\",\n      \"pmids\": [\"33658484\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"FBXO4 functions as an E3 ubiquitin ligase for MCL-1, interacting with MCL-1 and promoting its ubiquitination and proteasomal degradation. Knockdown of FBXO4 elevates MCL-1 protein levels and increases cell survival and chemotherapy resistance, while ectopic FBXO4 expression has opposite effects.\",\n      \"method\": \"Co-immunoprecipitation, ubiquitination assays, FBXO4 knockdown and overexpression, Western blotting for MCL-1 protein levels, cell viability assays\",\n      \"journal\": \"Cancer gene therapy\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP plus ubiquitination assay plus reciprocal KD/OE functional experiments; single lab, multiple orthogonal methods\",\n      \"pmids\": [\"28776569\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Caveolin-1 (Cav-1) regulates MCL-1 stability through direct protein-protein interaction, preventing MCL-1 ubiquitination and degradation during anoikis. Cav-1-overexpressing cells show elevated MCL-1 and MCL-1-Cav-1 complex, while Cav-1 knockdown reduces MCL-1 and increases its ubiquitination.\",\n      \"method\": \"Co-immunoprecipitation, immunocytochemistry, Cav-1 overexpression and knockdown, ubiquitination assays, anoikis assays\",\n      \"journal\": \"American journal of physiology. Cell physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP plus ubiquitination assay plus reciprocal gain/loss-of-function; single lab, multiple orthogonal methods\",\n      \"pmids\": [\"22277751\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"MCL-1 is a master regulator of fatty acid oxidation (FAO) in MCL-1-dependent hematologic cancer cells. FAO regulation by MCL-1 is independent of its anti-apoptotic activity, as demonstrated by metabolomic, proteomic, and genomic profiling of MCL-1-dependent leukemia cells lacking an intact apoptotic pathway. Genetic deletion of Mcl-1 results in transcriptional downregulation of FAO pathway proteins, making cells susceptible to glucose withdrawal-triggered cell death even when apoptosis is blocked.\",\n      \"method\": \"Mcl-1 genetic deletion, metabolomic profiling, proteomic profiling, genomic profiling, glucose withdrawal experiments in apoptosis-deficient cells\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — genetic deletion with metabolomic/proteomic/genomic profiling plus functional apoptosis-independent validation using multiple orthogonal approaches\",\n      \"pmids\": [\"36198266\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"MCL-1 suppresses non-selective starvation-induced autophagy but promotes selective autophagy (mitophagy) of dysfunctional mitochondria. MCL-1 interacts with the mitophagy receptor Bnip3, and this interaction increases during mitochondrial stress. MCL-1-mediated mitochondrial clearance is partially dependent on its LC3-interacting regions (LIR motifs), as mutation of LIR sites significantly reduces MCL-1-mediated mitochondrial clearance.\",\n      \"method\": \"Cardiac-specific MCL-1 overexpression, autophagic flux assays, mitophagy assays, co-immunoprecipitation of MCL-1 with Bnip3, LIR motif mutagenesis, mitochondrial depolarization experiments\",\n      \"journal\": \"Cells\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP plus LIR mutagenesis plus functional autophagy/mitophagy assays; single lab, multiple orthogonal methods\",\n      \"pmids\": [\"35563775\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"The transmembrane domain (TMD) of MCL-1 forms homooligomers in the mitochondrial membrane and competes with full-length MCL-1 for its antiapoptotic function. MCL-1 TMD can also heterooligomerize with the Bok TMD predominantly at the mitochondrial membrane. Coexpression of MCL-1 and Bok TMDs increases ER-mitochondria associated membranes. Cancer-associated somatic mutations in the MCL-1 TMD alter the TMD interaction pattern to enhance MCL-1 antiapoptotic activity.\",\n      \"method\": \"Oligomerization assays, subcellular fractionation, apoptosis assays, mutagenesis of cancer-associated TMD variants, ER-mitochondria contact site analysis\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct TMD oligomerization assays plus mutagenesis plus functional apoptosis readout; single lab, multiple orthogonal methods\",\n      \"pmids\": [\"33093207\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"STAT3 and MCL-1 are direct interacting partners during embryo implantation, with the interaction regulated by estrogen and progesterone. Association of MCL-1 with STAT3 modulates MCL-1's normal anti-apoptotic activity, resulting in pro-apoptotic effects and decreased cellular invasion in MCF7 cells.\",\n      \"method\": \"MALDI-TOF analysis, far-western analysis, co-localization studies, co-transfection experiments, apoptosis and invasion assays\",\n      \"journal\": \"Journal of cell science\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — co-localization and co-transfection without reciprocal Co-IP; single lab, limited mechanistic follow-up for STAT3 as direct binding partner\",\n      \"pmids\": [\"24481815\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"During apoptosis, MCL-1 protein levels decline through both caspase-dependent (affecting mRNA) and proteasome-dependent (affecting protein) pathways. Staurosporine reduces MCL-1 mRNA through caspase-dependent transcriptional inhibition of the MCL-1 promoter, while aspirin reduces MCL-1 protein via cap-dependent translation inhibition with eIF2α phosphorylation, without affecting mRNA.\",\n      \"method\": \"Caspase inhibitor (Z-VAD.fmk), proteasome inhibitor (MG132), actinomycin D, luciferase reporter constructs for MCL-1 promoter, IRES-luciferase translation reporter, eIF2α phosphorylation assays, cycloheximide treatment\",\n      \"journal\": \"Archives of biochemistry and biophysics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reporter assays plus pharmacological pathway dissection plus multiple orthogonal approaches; single lab\",\n      \"pmids\": [\"12941295\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Notch1 directly controls the MCL-1 promoter through a conserved CSL/RBP-Jκ binding site. Notch1 upregulation in macrophages treated with PPD or infected with BCG correlates with MCL-1 upregulation. Silencing Notch1 decreases MCL-1 protein expression, and gamma-secretase inhibition (blocking Notch processing) reduces both Notch1 and MCL-1 levels with increased apoptosis.\",\n      \"method\": \"Chromatin immunoprecipitation (ChIP) of Notch1 at MCL-1 promoter, gamma-secretase inhibitor experiments, Notch1 siRNA knockdown, promoter sequence analysis, Western blotting and RT-PCR\",\n      \"journal\": \"Cellular & molecular immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP establishing direct promoter binding plus pharmacological and siRNA validation; single lab, multiple orthogonal methods\",\n      \"pmids\": [\"23872918\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Phosphorylation of Bim regulates MCL-1 stability and binding specificity. Constitutively phosphorylated Bim stabilizes MCL-1 in RPCI-WM1 cells. Phospho-mimetic and unphosphorylatable Bim mutations result in altered MCL-1 stability and distinct Bim binding patterns to antiapoptotic proteins, linking Bim phosphorylation to enforcement of MCL-1 dependence.\",\n      \"method\": \"Phospho-mimetic and phospho-deficient Bim mutant expression, MCL-1 stability assays, co-immunoprecipitation to assess Bim-MCL-1 binding, cell viability assays\",\n      \"journal\": \"The FEBS journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — phospho-mutant analysis plus Co-IP plus functional stability assay; single lab, multiple approaches\",\n      \"pmids\": [\"29775995\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"During mitotic arrest (taxol treatment), proteasome-mediated MCL-1 degradation occurs independently of APC/C-Cdc20, FBW7, or MULE E3 ubiquitin ligases. MCL-1 is continuously synthesized during mitosis. Blocking proteasome-mediated degradation inhibits taxol-induced mitotic apoptosis in an MCL-1-dependent manner. Overexpression of MCL-1 extends the time from mitotic entry to exit under taxol, while MCL-1 inhibition accelerates mitotic exit, suggesting MCL-1 competes with Cyclin B1 for the proteolysis machinery.\",\n      \"method\": \"Proteasome inhibitor experiments, siRNA knockdown of APC/C-Cdc20/FBW7/MULE, time-lapse microscopy, MCL-1 overexpression and inhibition, Cyclin B1 degradation assays\",\n      \"journal\": \"Oncotarget\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple E3 ligase knockdowns plus MCL-1 gain/loss-of-function plus time-lapse functional analysis; single lab, multiple orthogonal approaches\",\n      \"pmids\": [\"26769847\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"A novel 'reverse BH3' (rBH3) binding motif was identified for MCL-1 through phage display screening. rBH3 peptides bind selectively to the BH3-binding groove of MCL-1 over Bcl-xL, with a reverse organization of conserved hydrophobic and acidic residues compared to canonical BH3 sequences.\",\n      \"method\": \"Phage display library screening with Sabutoclax as competitor, NMR spectroscopy, fluorescence polarization displacement assays, alanine scanning\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — NMR plus fluorescence polarization plus alanine scanning; single lab, multiple biophysical methods\",\n      \"pmids\": [\"21953453\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"MCL-1 inhibitors (AMG-176 and AZD5991) induce MCL-1 protein stability predominantly through defective MCL-1 ubiquitination via enhanced deubiquitination (through USP9x) and dissociation of MCL-1 from Noxa (leading to Noxa degradation) and from Bak/Bax. Mule E3 ligase is destabilized. ERK-mediated MCL-1 Thr163 phosphorylation partially contributes. WP1130 (global DUB inhibitor) abrogates MCL-1 induction.\",\n      \"method\": \"Protein half-life assays, reverse-phase protein array, Co-IP, phosphorylation analysis, ubiquitination and de-ubiquitination assays in vitro, DUB inhibitor experiments, molecular simulation and modeling\",\n      \"journal\": \"Clinical cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP plus in vitro ubiquitination assays plus pharmacological DUB inhibition; single lab, multiple orthogonal methods\",\n      \"pmids\": [\"36346691\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"MCL-1 is a multifunctional anti-apoptotic BCL-2 family protein that primarily sequesters pro-apoptotic proteins (BAK, BAX, BIM) at the outer mitochondrial membrane to prevent cytochrome c release; its stability is governed by a complex post-translational network involving phosphorylation (at Ser159/Thr163 by GSK3β, PKCθ, CDK5; dephosphorylated by PP2A) targeting it for ubiquitination by multiple E3 ligases (FBW7, MULE, FBXO4, FBXO4, TRAF4-Akt axis) and stabilization by deubiquitinases (USP9X, USP13), with additional ubiquitin-independent proteasomal degradation via the 20S proteasome; beyond apoptosis regulation, MCL-1 localizes to the mitochondrial matrix to support mitochondrial respiration and morphology, is recruited to DNA double-strand break sites where it promotes ATR-Chk1 checkpoint signaling, acts as a functional switch between HR and NHEJ DNA repair via direct interaction with Ku through its BH1/BH3 domains, interacts with and activates Akt through its PEST domain, regulates fatty acid oxidation transcriptionally independent of its apoptotic function, and modulates mitophagy through LC3-interacting regions and interaction with Bnip3.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"MCL-1 is an anti-apoptotic BCL-2 family protein that maintains pro-apoptotic effectors in an inactive state at the mitochondrion to prevent commitment to programmed cell death [#0]. Its core survival function rests on its BH3-binding groove, which holds BAK in an inactive complex; loss of MCL-1 releases BAK and licenses apoptosis [#0], and an allosteric cysteine (C286) distant from this groove tunes BH3 binding and BAX suppression [#12]. The anti-apoptotic activity is restricted to the outer mitochondrial membrane, whereas a separable matrix-localized pool supports mitochondrial respiration and morphology — cardiac ablation of Mcl-1 causes fatal cardiomyopathy with respiratory defects that persist even when apoptosis is blocked by Bax/Bak co-deletion [#4, #5]. Beyond apoptosis, MCL-1 acts as a transcriptional master regulator of fatty acid oxidation independently of its apoptotic role [#22], is recruited to DNA double-strand breaks to support ATR-Chk1 checkpoint signaling and genome integrity [#3], and functions as a switch between homologous recombination and non-homologous end-joining by directly binding the Ku complex through its BH1/BH3 domains [#10]. MCL-1 also directly binds and activates Akt via its PEST domain [#11] and modulates mitophagy through LC3-interacting regions and interaction with the receptor Bnip3 [#23]. The protein is short-lived and its abundance is set by a dense post-translational network: GSK3\\u03b2-, PKC\\u03b8- and ERK-dependent phosphorylation (notably at Ser159/Thr163) primes it for ubiquitination by E3 ligases including SCF-Fbw7 and FBXO4, opposed by PP2A-mediated dephosphorylation, stabilizing deubiquitinases (USP13, USP9x), and competing factors such as Skp2 and TRAF4 [#6, #7, #8, #16, #17, #18, #19, #20, #31]. MCL-1 can additionally be degraded ubiquitin-independently by the 20S proteasome [#2], and its pro-survival versus pro-death balance is set upstream by alternative splicing that produces MCL-1L and MCL-1S isoforms [#13, #14, #15].\",\n  \"teleology\": [\n    {\n      \"year\": 2003,\n      \"claim\": \"Established the core anti-apoptotic mechanism: that MCL-1 directly restrains a pro-apoptotic effector rather than acting only as a general survival signal.\",\n      \"evidence\": \"Co-IP of MCL-1 with BAK plus rescue experiments in adenovirus-infected cells where E1A-driven MCL-1 loss releases BAK and triggers apoptosis\",\n      \"pmids\": [\"14633975\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not resolve the structural basis of the BAK interaction\", \"Did not address other effectors (BAX, BIM) in the same system\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Showed MCL-1 abundance is controlled at multiple layers during apoptosis, distinguishing transcriptional, translational and proteasomal routes of loss.\",\n      \"evidence\": \"Promoter and IRES reporter assays, caspase and proteasome inhibitors, and eIF2\\u03b1 phosphorylation analysis\",\n      \"pmids\": [\"12941295\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Did not identify the responsible E3 ligase\", \"Mechanism linking caspase activity to mRNA loss not defined\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Mapped a specific kinase-to-degradation axis by identifying Ser159 phosphorylation as a degradation trigger under lipotoxic stress.\",\n      \"evidence\": \"PKC\\u03b8 genetic deletion, rottlerin inhibition, phospho-Ser159 immunoblot, and S159A mutant in primary hepatocytes\",\n      \"pmids\": [\"19734538\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not identify the E3 ligase acting downstream of Ser159 phosphorylation\", \"Generalizability beyond hepatocyte lipoapoptosis untested\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Demonstrated MCL-1 degradation can be entirely ubiquitin-independent, revealing a 20S-proteasome route alongside the canonical ubiquitin pathway.\",\n      \"evidence\": \"Lysine-less MCL-1(KR) mutant, E1 inhibition, and cell-free 20S proteasome degradation of in vitro-translated MCL-1\",\n      \"pmids\": [\"20385764\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Relative contribution of ubiquitin-dependent vs independent routes in vivo unclear\", \"What targets MCL-1 to the 20S proteasome unresolved\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Extended MCL-1 function into the DNA damage response, showing a nuclear/DSB role in checkpoint signaling distinct from mitochondrial apoptosis.\",\n      \"evidence\": \"Co-IP with \\u03b3-H2AX and NBS1, site-specific DSB recruitment, and delayed Chk1 phosphorylation in Mcl-1\\u2212/\\u2212 MEFs\",\n      \"pmids\": [\"20647761\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct molecular partner at the break site not defined here\", \"How nuclear recruitment is regulated unknown\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Resolved that MCL-1's apoptotic and metabolic functions are spatially separated within the mitochondrion.\",\n      \"evidence\": \"Subcellular fractionation and localization-variant functional studies (review synthesizing direct experiments)\",\n      \"pmids\": [\"23026029\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Import mechanism into the matrix not defined\", \"Molecular partners of the matrix pool unidentified\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Provided in vivo proof that MCL-1 has an essential apoptosis-independent role in mitochondrial physiology.\",\n      \"evidence\": \"Cardiac-specific Mcl-1 KO with Bax/Bak epistasis, electron microscopy, and respiration assays\",\n      \"pmids\": [\"23788622\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular mechanism connecting MCL-1 to respiration not identified\", \"Matrix interacting partners unknown\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Linked MCL-1 turnover to anoikis and metastasis through a GSK-3\\u03b2/proteasome/Bim axis.\",\n      \"evidence\": \"GSK-3\\u03b2 and proteasome inhibition, MCL-1/Bim knockdown, and metastatic vs non-metastatic cell comparison with in vivo metastasis assay\",\n      \"pmids\": [\"18006817\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"E3 ligase downstream of GSK-3\\u03b2 not identified here\", \"Direct link to phospho-sites not mapped\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Identified caveolin-1 as a stabilizing binding partner that protects MCL-1 from ubiquitination during anoikis.\",\n      \"evidence\": \"Co-IP, reciprocal Cav-1 overexpression/knockdown, and ubiquitination assays\",\n      \"pmids\": [\"22277751\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Binding interface not mapped\", \"Whether Cav-1 blocks a specific E3 unknown\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Identified tankyrase 1 as an N-terminal binding partner regulating MCL-1 levels independent of ADP-ribosylation.\",\n      \"evidence\": \"Yeast two-hybrid, Co-IP, truncation mapping, and overexpression functional assays\",\n      \"pmids\": [\"12475993\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism of level reduction not defined\", \"Physiological relevance untested\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Established splicing factor control of the MCL-1L/MCL-1S balance, defining an upstream determinant of pro- vs anti-apoptotic output.\",\n      \"evidence\": \"SRSF1/SRSF5 siRNA knockdown with RT-PCR splicing readout in breast cancer cells\",\n      \"pmids\": [\"23284704\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct binding sites not mapped in this study\", \"Context-dependence mechanism unclear\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Expanded the splicing regulatory network and mapped binding sites controlling the pro-apoptotic MCL-1S switch.\",\n      \"evidence\": \"hnRNP F/H1/K knockdown, RNA-IP, MCL-1 minigene, and apoptosis assays\",\n      \"pmids\": [\"30468106\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Interplay with SR proteins not resolved\", \"In vivo relevance untested\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Defined transcriptional control of MCL-1 by Notch1 through a direct promoter element in an immune context.\",\n      \"evidence\": \"ChIP at the MCL-1 promoter, gamma-secretase inhibition, and Notch1 siRNA in macrophages\",\n      \"pmids\": [\"23872918\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Cofactors at the CSL site not defined\", \"Generalizability beyond macrophages unknown\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Linked Fbw7 loss to MCL-1 overexpression and BH3-mimetic resistance, establishing a clinically relevant degradation pathway.\",\n      \"evidence\": \"Ubiquitination assays, GSK3 inhibition, Fbw7 reconstitution and Mcl-1 knockdown in T-ALL lines\",\n      \"pmids\": [\"21608150\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Phospho-degron not directly mapped here\", \"Dependence on specific phospho-sites not defined\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Proposed STAT3 as a context-dependent partner that inverts MCL-1 function toward pro-apoptotic outcomes during implantation.\",\n      \"evidence\": \"MALDI-TOF, far-western, co-localization and co-transfection with apoptosis/invasion assays\",\n      \"pmids\": [\"24481815\"],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No reciprocal Co-IP to confirm direct binding\", \"Mechanism of functional inversion not defined\", \"Single-lab limited follow-up\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Identified an allosteric regulatory cysteine (C286) outside the BH3 groove that controls MCL-1's effector-suppressing capacity.\",\n      \"evidence\": \"Covalent C286 modification, C286W mutagenesis, in vitro BH3 binding and BAX suppression assays, and HDX-MS\",\n      \"pmids\": [\"27159560\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Endogenous physiological ligand of C286 unknown\", \"Whether oxidation modifies C286 in cells untested\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Defined a mitosis-specific, ligase-independent route of MCL-1 degradation that gates taxol-induced mitotic apoptosis.\",\n      \"evidence\": \"siRNA of APC/C-Cdc20, FBW7, MULE, proteasome inhibition, time-lapse microscopy and MCL-1 gain/loss-of-function\",\n      \"pmids\": [\"26769847\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"The degradation machinery used during mitosis not identified\", \"Mechanism of competition with Cyclin B1 unclear\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Characterized a distinct 'reverse BH3' binding mode selective for the MCL-1 groove, informing inhibitor design.\",\n      \"evidence\": \"Phage display, NMR, fluorescence polarization displacement and alanine scanning\",\n      \"pmids\": [\"21953453\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No endogenous rBH3 protein partner identified\", \"Cellular relevance untested\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Coupled Hsp90 inhibition to MCL-1 degradation via GSK3\\u03b2-dependent phosphorylation and FBW7 recruitment, validated in vivo.\",\n      \"evidence\": \"GSK3\\u03b2 inhibition, phospho-mutant knock-in, ubiquitination assays and xenografts\",\n      \"pmids\": [\"28619760\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Exact phospho-degron residues not fully delineated\", \"Breadth across tumor types untested\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Identified FBXO4 as an additional E3 ligase for MCL-1 influencing chemoresistance.\",\n      \"evidence\": \"Co-IP, ubiquitination assays, and reciprocal FBXO4 knockdown/overexpression\",\n      \"pmids\": [\"28776569\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Phospho-dependence of FBXO4 recognition not defined\", \"Relationship to Fbw7 not resolved\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Revealed a nuclear function of MCL-1 as an HR/NHEJ switch via direct binding to Ku, decoupling DNA repair control from apoptosis.\",\n      \"evidence\": \"CRISPR/shRNA depletion, HR/NHEJ reporters, Co-IP with Ku, BH1/BH3 domain mutants, cell-cycle analysis and xenografts with MI-223\",\n      \"pmids\": [\"29227281\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How MCL-1 is recruited to chromatin not fully defined\", \"Structural basis of Ku inhibition unresolved\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Showed that Bim phosphorylation feeds back to control MCL-1 stability and binding specificity, enforcing MCL-1 dependence.\",\n      \"evidence\": \"Phospho-mimetic/deficient Bim mutants, Co-IP, and MCL-1 stability and viability assays\",\n      \"pmids\": [\"29775995\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Kinase responsible for Bim phosphorylation not defined here\", \"Generalizability beyond the WM model untested\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Established a direct MCL-1\\u2013Akt interaction in which the PEST domain activates Akt, defining a pro-tumorigenic signaling role.\",\n      \"evidence\": \"CRISPR/shRNA depletion, Co-IP, PEST/PH domain mapping, Akt activity assays, xenografts and the disruptor PH-687\",\n      \"pmids\": [\"31662324\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural model of the PEST/PH interface not solved\", \"Relationship to mitochondrial MCL-1 pool unclear\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Showed the MCL-1 transmembrane domain self- and hetero-oligomerizes and that cancer mutations in it enhance anti-apoptotic activity.\",\n      \"evidence\": \"Oligomerization and fractionation assays, Bok TMD heterooligomerization, ER-mitochondria contact analysis, and TMD-variant mutagenesis\",\n      \"pmids\": [\"33093207\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Physiological role of TMD oligomers in normal cells unclear\", \"Structural arrangement of oligomers undefined\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Identified USP13 as a deubiquitinase that stabilizes MCL-1, adding a stabilizing arm to the turnover network.\",\n      \"evidence\": \"Co-IP, ubiquitination assays, siRNA, proliferation assays and tissue IHC correlation in cervical cancer\",\n      \"pmids\": [\"33627786\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Binding interface not mapped\", \"Whether USP13 competes with specific E3s untested\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Established PP2A as the phosphatase that opposes degradative phosphorylation at Ser159/Thr163, completing a kinase-phosphatase switch.\",\n      \"evidence\": \"Phosphatase siRNA screen, okadaic acid inhibition, phospho-specific blotting and half-life measurements in myeloma\",\n      \"pmids\": [\"33658484\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct PP2A\\u2013MCL-1 contact not demonstrated\", \"Targeting subunit of PP2A unknown\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Defined MCL-1 as a transcriptional master regulator of fatty acid oxidation independent of apoptosis, a genuinely separable function.\",\n      \"evidence\": \"Mcl-1 genetic deletion with metabolomic/proteomic/genomic profiling and glucose-withdrawal lethality in apoptosis-deficient leukemia cells\",\n      \"pmids\": [\"36198266\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How MCL-1 controls FAO gene transcription mechanistically unknown\", \"Whether this requires a specific subcellular pool unresolved\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Connected MCL-1 to selective mitophagy through Bnip3 binding and LIR motifs, distinguishing it from suppression of bulk autophagy.\",\n      \"evidence\": \"Cardiac MCL-1 overexpression, autophagic flux and mitophagy assays, Co-IP with Bnip3, and LIR mutagenesis\",\n      \"pmids\": [\"35563775\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"LIR-mediated LC3 binding not directly biophysically confirmed\", \"Crosstalk with apoptotic function unresolved\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Identified Skp2 as a stabilizing factor that competes with FBW7 to control MCL-1-dependent radioresistance.\",\n      \"evidence\": \"Co-IP, ubiquitination analysis, Skp2 CRISPR knockout, and xenografts in colorectal cancer\",\n      \"pmids\": [\"35301297\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism of competition with FBW7 not structurally defined\", \"Whether Skp2 acts catalytically or by occlusion unclear\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Connected TRAF4 to MCL-1 stability through a TRAF4-Akt-GSK3\\u03b2 axis converging on Ser159 and the deubiquitinase JOSD1.\",\n      \"evidence\": \"Co-IP of TRAF4 with Akt and MCL-1, GSK3\\u03b2 activity assays, phospho-S159 blotting, TRAF4 KO and xenografts\",\n      \"pmids\": [\"36535926\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct JOSD1\\u2013MCL-1 interaction interface not mapped\", \"Hierarchy among the many stabilizing factors unresolved\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Showed that BH3-mimetic MCL-1 inhibitors paradoxically stabilize MCL-1 protein by enhancing USP9x deubiquitination and dissociating partners.\",\n      \"evidence\": \"Half-life assays, RPPA, Co-IP, in vitro ubiquitination/deubiquitination, DUB inhibitor (WP1130) and modeling\",\n      \"pmids\": [\"36346691\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism by which inhibitor binding triggers USP9x recruitment unclear\", \"Clinical implications of induced stabilization untested\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How MCL-1's spatially and functionally distinct activities — outer-membrane apoptosis suppression, matrix respiration, nuclear DNA-repair switching, Akt activation and FAO transcription — are coordinated and selectively regulated by its turnover network remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No unifying model links the subcellular pools to specific degradation routes\", \"Structural basis for non-apoptotic interactions (Ku, Akt, Bnip3) undefined\", \"Mechanism of transcriptional FAO control unknown\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140313\", \"supporting_discovery_ids\": [0, 12]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [0, 11, 10]},\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [22]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005741\", \"supporting_discovery_ids\": [4, 5, 24]},\n      {\"term_id\": \"GO:0005739\", \"supporting_discovery_ids\": [4, 5]},\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [3, 10]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [0, 4]},\n      {\"term_id\": \"R-HSA-73894\", \"supporting_discovery_ids\": [3, 10]},\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [22]},\n      {\"term_id\": \"R-HSA-9612973\", \"supporting_discovery_ids\": [23]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"BAK\", \"BIM\", \"BAX\", \"Ku\", \"AKT\", \"BNIP3\", \"USP13\", \"FBW7\"],\n    \"other_free_text\": []\n  }\n}\n```","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":7,"faith_total":7,"faith_pct":100.0}}